[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 95 of about 95
1. Sherwani RK, Kumar A, Raza MH: Haemorrhoids or anal melanoma, importance of preoperative histopathological examination: a case report. Pol J Pathol; 2010;61(1):46-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorrhoids or anal melanoma, importance of preoperative histopathological examination: a case report.
  • Haemorrhoids are the most common lesion affecting the anorectal region, whereas anal melanoma constitutes only 1% to 3% of all malignant tumours of anal canal.
  • We report a case of a female with classical clinical presentation of prolapsed haemorrhoids which on histopathological evaluation was found to be malignant melanoma.
  • The case highlights the significance of exact diagnosis prior to any surgical intervention.
  • [MeSH-major] Hemorrhoids. Melanoma
  • [MeSH-minor] Anus Neoplasms. Humans. Rectum. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Hemorrhoids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496274.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


2. Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I: Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report. Acta Med Okayama; 2008 Dec;62(6):421-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
  • Anorectal melanoma is a rare malignant tumor with a poor prognosis.
  • In this report, we present a patient with anorectal melanoma who has survived for 9 years after endoscopic mucosal resection.
  • An 85-year-old man was referred to our hospital for further examination and treatment of an anal tumor 2 cm in size.
  • Endoscopic mucosal resection was performed, and the tumor was diagnosed as a malignant melanoma.
  • Although melanoma recurred 4 times thereafter, endoscopic mucosal resection was performed for each recurrent lesion.
  • [MeSH-major] Anal Canal / surgery. Endoscopy / methods. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122689.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, Rozzo C: Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer; 2007;6:8
Hazardous Substances Data Bank. EUGENOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells.
  • BACKGROUND: Malignant melanoma is one of the most aggressive skin cancer and chemotherapeutic agents currently in use are still unsatisfactory.
  • Prevention and early diagnosis are the only effective tools against this tumour whose incidence and mortality rates are highly increased during the last decades in fair skin populations.
  • Aim of this work was to identify and test new compounds with antiproliferative and cytotoxic activity on melanoma cells.
  • We tested eugenol together with six natural and synthetic eugenol-related compounds for their capability to inhibit cell growth on primary melanoma cell lines established from patients' tissue samples.
  • RESULTS: Eugenol and isoeugenol monomers and their respective O-methylated forms did not show to inhibit melanoma cells proliferation.
  • Then IC50 and minimal effective doses and times have been established for the melanoma cell lines tested.
  • Cytotoxic activity and apoptosis induced by treating melanoma cells with eugenol-related biphenyls was partially dependent by caspase activation.
  • CONCLUSION: Our findings demonstrate that the eugenol related biphenyl (S)-6,6'-dibromo-dehydrodieugenol elicits specific antiproliferative activity on neuroectodermal tumour cells partially triggering apoptosis and its activity should be further investigated on in vivo melanoma models in order to evaluate the real anticancer effectiveness on such tumour.
  • [MeSH-major] Biphenyl Compounds / chemistry. Cell Proliferation / drug effects. Eugenol / analogs & derivatives. Eugenol / pharmacology. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BIPHENYL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Oct 13;24(45):6785-95 [16007159.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3263-9 [16101137.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57 [16912267.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] Blood. 2005 Jul 15;106(2):690-7 [15802533.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2000 Oct;48(10):1467-9 [11045452.001]
  • [Cites] Phytother Res. 2000 Nov;14(7):495-500 [11054837.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Toxicology. 2002 Aug 1;177(1):39-54 [12126794.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1341-7 [12826035.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3492-502 [12960142.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35501-7 [12816951.001]
  • [Cites] J Pharm Pharmacol. 2003 Nov;55(11):1583-91 [14713371.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4693-701 [14981915.001]
  • [Cites] Int J Food Microbiol. 2004 Aug 1;94(3):223-53 [15246235.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):435-8 [15274056.001]
  • [Cites] Cancer Lett. 2004 Nov 25;215(2):129-40 [15488631.001]
  • [Cites] Cancer Res. 1977 May;37(5):1364-71 [856461.001]
  • [Cites] Mutat Res. 1981 Dec;90(4):355-63 [7335107.001]
  • [Cites] N Engl J Med. 1984 Jan 5;310(1):50-1 [6689743.001]
  • [Cites] Anal Biochem. 1989 Oct;182(1):16-9 [2604040.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):578-9 [2307545.001]
  • [Cites] Biochem Pharmacol. 1994 Feb 9;47(3):549-53 [8117323.001]
  • [Cites] Pigment Cell Res. 1994 Apr;7(2):116-22 [8066017.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):853-61 [7850799.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Sep;39(9):2000-7 [8540706.001]
  • [Cites] Bioorg Med Chem. 1997 Aug;5(8):1715-23 [9313872.001]
  • [Cites] Chem Biol. 1998 May;5(5):R97-103 [9578633.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):262-7 [10188729.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):268-74 [10188730.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5812-9 [15574415.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):193-200 [15711935.001]
  • [Cites] Nat Med. 2005 Jul;11(7):725-30 [16015365.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2337s-2341s [16609055.001]
  • (PMID = 17233906.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 2L9GJK6MGN / diphenyl; 3T8H1794QW / Eugenol
  • [Other-IDs] NLM/ PMC1785384
  •  go-up   go-down


Advertisement
4. Martínez-Hernández-Magro P, Villanueva-Sáenz E, Chávez-Colunga LB: [Anal malignant melanoma. Case report and literature review]. Rev Gastroenterol Mex; 2009;74(1):39-44
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal malignant melanoma. Case report and literature review].
  • [Transliterated title] Melanoma maligno anal. Reporte de casos y revisión de la literatura.
  • OBJECTIVE: To present two cases of anorectal malignant melanoma as due to its non specific presentation and rarity they are often misdiagnosed like hemorrhoids.
  • BACKGROUND: Anal melanomas are rare tumors that constitute less than 1% of the malignant colorectal tumors and represent both a diagnostic and therapeutic challenge to physicians.
  • Melanomas are often misdiagnosed by a lot of anorectal conditions and diagnosis must be suspected in patients with an anal mass.
  • CASE REPORT: We present two anorectal cases of malignant melanoma treated by wide local excision, the principal complain in both patients was the presence of an anal mass and bleeding.
  • CONCLUSIONS: Anal melanoma is a rare entity with a poor prognosis.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666318.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  •  go-up   go-down


5. Yaramov N, Sokolov M, Angelov K, Petrov B, Pavlov V: [Malignant melanoma of the anus and rectum]. Khirurgiia (Sofiia); 2010;(2-3):5-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the anus and rectum].
  • There is approximately 300 cases of malignant melanoma written in the world literature.
  • We write up 13 operated from us for 15 years cases of melanoma of the anus and rectum.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972686.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


6. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


7. Kakutani K, Doita M, Nishida K, Miyamoto H, Kurosaka M: Radiculopathy due to malignant melanoma in the sacrum with unknown primary site. Eur Spine J; 2008 Sep;17 Suppl 2:S271-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.
  • Melanoma is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.
  • To report a very rare case of malignant melanoma in the sacrum with unknown primary origin.
  • The pathological diagnosis was malignant melanoma.
  • No obvious primary malignant melanoma was detected on the skin surface, on the oral or anal mucosa, or in the fundus oculi.
  • However the patient died nine months after initial diagnosis.
  • Malignant melanoma in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.
  • The melanoma could have been a metastatic tumor of the sacrum, although the primary site was not detected.
  • The incidence of primary melanoma is increasing faster than any other cancer.
  • Thus treatment of patients with spinal metastasis of melanoma is an important challenge for orthopedic surgeons.
  • [MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):78-80 [10711643.001]
  • [Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]
  • [Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]
  • [Cites] Oncology. 1972;26(2):265-70 [5049921.001]
  • [Cites] Cancer. 1972 Dec;30(6):1469-72 [4641758.001]
  • [Cites] Br J Surg. 1977 Nov;64(11):805-8 [588977.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):98-104 [7352784.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]
  • [Cites] CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26 [2049635.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6 [8588172.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Mar;77(3):307-9 [8600878.001]
  • [Cites] Br J Surg. 1967 Jul;54(7):651-8 [6026989.001]
  • (PMID = 18075762.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2525896
  •  go-up   go-down


8. Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I: Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet; 2007 Mar 08;8:10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.
  • BACKGROUND: Cutaneous Malignant Melanoma causes over 75% of skin cancer-related deaths, and it is clear that many factors may contribute to the outcome.
  • Some polymorphisms are known to influence gene expression, protein activity, stability, and interactions, and they were shown to be associated with certain tumor phenotypes and cancer risk.
  • METHODS: We tested seven polymorphisms within the MMP-9 gene in 1002 patients with melanoma in order to evaluate germline genetic variants and their association with progression and known risk factors of melanoma.
  • RESULTS: We found that reference alleles were present in higher frequency in patients who tend to sunburn, have family history of melanoma, higher melanoma stage, intransit metastasis and desmoplastic melanomas among others.
  • However, after adjustment for age, sex, phenotypic index, moles, and freckles only Q279R, P574R and R668Q had significant associations with intransit metastasis, propensity to tan/sunburn and primary melanoma site.
  • CONCLUSION: This study does not provide strong evidence for further investigation into the role of the MMP-9 SNPs in melanoma progression.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):70-4 [10428474.001]
  • [Cites] Cell Biochem Funct. 2007 Jul-Aug;25(4):433-41 [16615041.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8924-31 [15604254.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1322-5 [15894695.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5158-66 [16033831.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):1000-1; author reply 1002-3 [15856460.001]
  • [Cites] Int J Biol Markers. 2005 Oct-Dec;20(4):242-8 [16398406.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):610-8 [16258177.001]
  • [Cites] Stroke. 1999 Dec;30(12):2612-6 [10582986.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2000 Mar 10;739(2):345-55 [10755378.001]
  • [Cites] Hum Hered. 2000 Mar-Apr;50(2):133-9 [10799972.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):337-44 [10951266.001]
  • [Cites] Cancer Lett. 2001 Jan;162 Suppl:S49-S55 [11164190.001]
  • [Cites] In Vivo. 2001 Jan-Feb;15(1):57-64 [11286131.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):534-40 [11544020.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):158-63 [11687599.001]
  • [Cites] J Mol Biol. 2001 Nov 2;313(4):903-19 [11697912.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):432-8 [11802203.001]
  • [Cites] Mol Hum Reprod. 2002 May;8(5):494-501 [11994547.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):765-72 [12359218.001]
  • [Cites] Methods Mol Biol. 2003;212:189-95 [12491911.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Biotechniques. 2003 Jun;34(6):1288-92, 1294-5 [12813898.001]
  • [Cites] Anal Biochem. 2003 Nov 15;322(2):283-6 [14596841.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8221-5 [14678978.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):221-33 [15036262.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):665-70 [9284814.001]
  • [Cites] Biometrics. 1997 Dec;53(4):1253-61 [9423247.001]
  • [Cites] Circulation. 1999 Apr 13;99(14):1788-94 [10199873.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:212-27 [10415733.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):207-11 [16718267.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):92-6 [16581051.001]
  • [Cites] Cancer Lett. 2006 Sep 8;241(1):59-63 [16466849.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):19-25 [15565457.001]
  • (PMID = 17346338.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA020449; United States / NCI NIH HHS / CA / 5 R25 CA 20449-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC1831467
  •  go-up   go-down


9. Olsha O, Mintz A, Gimon Z, Gold Deutch R, Rabin I, Halevy A, Reissman P: Anal melanoma in the era of sentinel lymph node mapping: a diagnostic and therapeutic challenge. Tech Coloproctol; 2005 Apr;9(1):60-2
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma in the era of sentinel lymph node mapping: a diagnostic and therapeutic challenge.
  • Melanoma of the anal canal is a rare malignancy that often has an atypical presentation.
  • We explored the possibility of applying the technique of sentinel lymph node (SLN) mapping to anal melanoma.
  • SLN mapping was performed in 2 patients with anal melanoma.
  • One patient had a wide local excision of the anal lesion with house flap anoplasty, while the other had abdominoperineal resection with total mesorectal excision.
  • The technique of SLN mapping and biopsy is easily adapted to surgery for malignant melanoma of the anus.
  • [MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868503.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • Owing to delayed diagnosis and early metastases, the prognosis is often poor.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • The diagnosis of an AM is usually made using a biopsy.
  • Adjuvant immunohistological markers are the calcium-binding protein S-100, the melanoma antigen HMB-45, the melanoma-expressed protein Melan A, and microphthalmia-associated transcription factor (MiTF).
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • The tumour was histologically confirmed to be malignant melanoma.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


11. Sanli Y, Turkmen C, Kurul S, Taş F, Mudun A, Cantez S: Sentinel lymph node biopsy for the staging of anal melanoma: report of two cases. Ann Nucl Med; 2006 Nov;20(9):629-31
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for the staging of anal melanoma: report of two cases.
  • Primary melanoma of the anal region is a rare pathological entity and its prognosis is generally poor.
  • The aim of this report is to demonstrate the feasibility of the sentinel lymph node (SLN) procedure with combined technique in patients with anal melanoma.
  • We report of two cases with anal melanoma that had wide local excision of the primary lesion and was referred for further evaluation.
  • Consequently, we suggest that SLN procedure with combined technique is also a useful technique in malignant melanomas similar to other anal canal cancers.
  • [MeSH-major] Anus Neoplasms / diagnosis. Lymph Nodes / pathology. Melanoma / diagnosis. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Radionuclide Imaging / methods. Technetium Tc 99m Sulfur Colloid / pharmacology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294674.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


12. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • Tumors of the anal canal and anal margin are rare.
  • The other malignant tumors are very rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


13. Trzcinski R, Kujawski R, Mik M, Sygut A, Dziki L, Dziki A: Malignant melanoma of the anorectum--a rare entity. Langenbecks Arch Surg; 2010 Aug;395(6):757-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anorectum--a rare entity.
  • OBJECTIVE: Primary anorectal melanoma is a rare entity with a poor prognosis accounting for approximately 0.1-4.6% of anal tumours and 0.5-1.6% of all melanomas.
  • Almost 60% of patients have already disseminated disease at initial diagnosis.
  • METHOD: We report four cases of anorectal melanoma treated at our department from November 2006 to September 2008, as well as a review of the literature.
  • Three patients died on account of dissemination of melanoma, one patient is still alive.
  • CONCLUSION: Anal melanoma remains a deadly problem.
  • Clear guidelines for the therapy of anorectal melanoma have not been established.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Melanoma / diagnosis. Melanoma / therapy. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12 ):737-40 [18936790.001]
  • [Cites] Eur J Surg Oncol. 2009 Jul;35(7):757-62 [18602790.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):1012-7 [17122627.001]
  • [Cites] J Nippon Med Sch. 2007 Oct;74(5):377-81 [17965534.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] World J Gastroenterol. 2008 Mar 14;14(10):1633-5 [18330962.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):612-5 [17944970.001]
  • [Cites] World J Gastroenterol. 2006 Jun 7;12(21):3453-5 [16733870.001]
  • [Cites] Dis Colon Rectum. 2007 Jul;50(7):1004-10 [17468984.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):121-3 [12942268.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):164-5 [6692119.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Br J Surg. 2008 Nov;95(11):1401-7 [18844268.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • (PMID = 20066546.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


14. Stanojević G, Rancić Z, Jovanović M, Stojanović M, Mihailović D, Branković B: [Anal canal melanoma-- case report]. Acta Chir Iugosl; 2006;53(3):83-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal canal melanoma-- case report].
  • Anal canal melanoma is a rare disease comprising 1% of all colorectal ie. anal malignant tumours with very poor long term prognosis.
  • At the moment of diagnosis even 30% of the patients have distant metastases.
  • Modern approach to the anal canal melanoma treatment implies two types of intervention: wide local excision preserving the sphincter mechanism and abdominoperineal resection of the rectum.
  • The authors report on a 61 years old women in which anal canal melanoma with left inguinal lymphatic metastases was detected during the inspection of "haemorrhoids".
  • After the diagnosis was established, abdominoperineal resection of the rectum was performed with dissection of both inguinal regions.
  • [MeSH-major] Anus Neoplasms. Melanoma

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338206.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


15. Zhang S, Gao F, Chen LS, Tang ZJ, Liang JL, Wu Q: [Clinical analysis of anorectal malignant melanoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):309-11
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of anorectal malignant melanoma].
  • OBJECTIVE: To summarize the clinicopathological characteristics of primary anorectal malignant melanoma (AMM).
  • RESULTS: Anorectal malignant melanoma had a female predominance.
  • The onset of symptom was hematochezia, then anus prolapses.
  • 94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.
  • Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.
  • CONCLUSIONS: Anorectal malignant melanoma is often misdiagnosed,surgical procedure is the first choice for patients with AMM.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167248.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Dickson MA, Carvajal RD, Shah M, Tse AN, Dials H, Cane LM, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol. J Clin Oncol; 2009 May 20;27(15_suppl):e14511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.
  • Clinical activity included 2 partial responses (small bowel cancer, 10.3 m; bladder cancer, 10 m) and 1 complete response (mucosal melanoma 10.3 m).
  • Of 25 pts with colorectal cancer, 11 had as best response SD for > 3m (median 6 m, range 4.2-15.4 m), despite failing ≥ 1 irinotecan-containing regimen.
  • Promising clinical activity is seen in mucosal melanoma and irinotecan-refractory colon cancer. (Supported by NCI R01CA67819) [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Uchiyama S, Imamura N, Ohuchida J, Hiyoshi M, Nagano M, Marutsuka K, Akiyama Y, Chijiiwa K: Late recurrence of malignant melanoma in the duodenum. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1619-21
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence of malignant melanoma in the duodenum.
  • Melanoma is a malignancy originating from melanocytes.
  • The primary melanoma usually occurs on the skin, retina, anal canal or occasionally at other organs such as the esophagus, penis or vagina.
  • Although melanoma represents about one-third of all metastatic lesions in the gastrointestinal tract, metastasis of melanoma to the GI tract, detected radiologically or endoscopically, is relatively rare.
  • In most cases of malignant melanoma, recurrence and death occur within 10 years after treatment of the primary lesion.
  • We herein report a case showing a recurrence 17 years after extirpation of primary malignant melanoma in the foot.
  • A 65-year-old man, with a history of extirpation of a malignant melanoma in the sole of his foot 17 years before, presented with anorexia and severe anemia, and multiple duodenal tumors were pointed out with upper gastrointestinal endoscopy.
  • Histologic examination of the endoscopic biopsy specimen revealed proliferation of large polygonal cells with distinct nucleoli, and malignant melanoma was diagnosed immunohistochemically.
  • [MeSH-major] Duodenal Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102354.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CC chemokine receptor 9; 0 / Receptors, CCR
  •  go-up   go-down


18. Huang ZM, Li HZ, Xiao H, Ji ZG: [Melanoma adrenal metastasis: report of 3 cases and literature review]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1123-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanoma adrenal metastasis: report of 3 cases and literature review].
  • OBJECTIVE: To investigate the clinical diagnosis, treatment and prognosis of melanoma adrenal metastasis.
  • METHODS: A total of 48 cases of malignant melanoma from 1985 to 2007 were reviewed.
  • And three cases of melanoma adrenal metastasis were analyzed.
  • Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.
  • The other two cases underwent complete resection of melanoma metastasis.
  • When contralateral adrenal metastasis of melanoma was found 6 months later, left adrenalectomy laparoscopically was performed.
  • CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.
  • Patients with adrenal metastases from melanoma, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646432.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


19. Hanley KZ, Weiss SW, Logani S: Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis. Diagn Cytopathol; 2009 Jan;37(1):51-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis.
  • Fine-needle aspiration (FNA) is a minimally invasive, fast, and accurate diagnostic method for the evaluation of patients with locally recurrent or distant metastases of malignant melanoma.
  • In the vast majority of cases, the diagnosis is straightforward with the characteristic cytologic features well documented in the literature.
  • Divergent differentiation (chondroid, neural, myofibroblastic, and osteocartilagenous) in a melanoma is rare and can potentially create diagnostic challenges if the evaluator is unaware of the same.
  • We report a case of a 46-year-old female with a history of primary anal melanoma who presented with a groin mass.
  • The FNA of the groin mass showed a neoplasm rich in chondroid matrix and raised the possibility of a second primary mesenchymal neoplasm rather than metastasis from the patient's known primary anal melanoma.
  • A review of the histologic features of the anal melanoma showed divergent chondroid differentiation in the anal melanoma with the metastatic deposit in the groin exhibiting extensive chondroid differentiation.
  • [MeSH-major] Anus Neoplasms / pathology. Cartilage / pathology. Inguinal Canal / pathology. Lymph Nodes / pathology. Melanoma / secondary
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973120.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lyle PL, Amato CM, Fitzpatrick JE, Robinson WA: Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol; 2008 Jun;32(6):858-66
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma.
  • CCS and malignant melanoma (MM) share immunohistochemical profiles and ultrastructural features, but classic CCS has characteristic morphology with low mitotic activity and minimal pleomorphism.
  • This translocation has never been documented in cutaneous melanoma, and thus is regarded as specific for CCS.
  • Recent evidence suggests that primary "malignant melanomas" in unusual anatomic sites, most notably the gastrointestinal (GI) tract, may be CCS.
  • In total, we examined 7 cases: Four with no prior history of MM, 2 with histories of cutaneous MM, and 1 with an anal MM.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Melanoma / diagnosis. Sarcoma, Clear Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408594.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Nilsson PJ, Ragnarsson-Olding BK: Importance of clear resection margins in anorectal malignant melanoma. Br J Surg; 2010 Jan;97(1):98-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of clear resection margins in anorectal malignant melanoma.
  • BACKGROUND: Anorectal melanoma is rare and surgery is the recommended primary treatment.
  • METHODS: From the Swedish National Cancer Registry, 251 patients with anorectal melanoma were identified from 1960 to 1999.
  • CONCLUSION: Both APR and LE seem appropriate for anorectal melanoma provided clear margins can be achieved; prognosis is poor regardless of surgical approach.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20013935.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P: Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. Chin Med J (Engl); 2010 Mar 5;123(5):585-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma.
  • BACKGROUND: Anorectal malignant melanoma was a rare disease with extremely poor prognosis.
  • The aim of this study was to explore the clinical characteristic, diagnosis and treatment strategies of anorectal malignant melanoma.
  • METHODS: The data of 57 patients with anorectal malignant melanoma was collected and retrospectively analyzed.
  • RESULTS: Rectal bleeding and anal mass were found to be common symptoms of anorectal malignant melanoma.
  • The preoperative diagnosis rate of anorectal malignant melanoma was 48.6%.
  • CONCLUSIONS: This study identified no survival advantage to abdominoperineal resection in treatment of anorectal malignant melanoma, and we propose that wide local excision could be considered as the initial treatment of choice.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367986.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Tezuka K, Inaba Y, Hayashi K, Miura T, Moriya T, Takiguchi M, Isobe H, Watabe S, Yanagawa N: [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1709-12
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy].
  • We report a case on hemodialysis with liver metastases from anorectal malignant melanoma treated by dacarbazine (DTIC).
  • A 61-year-old man presented with anal bleeding.
  • An elastic soft mass was palpated in the anal canal, and a biopsy specimen was diagnosed as anorectal malignant melanoma histologically.
  • Subsequently, the patient died of respiratory failure 4 years after surgery, 1 year and 7 months after the diagnosis of multiple liver metastases.
  • We conclude that administration of DTIC undergoing hemodialysis for malignant melanoma with renal failure seems to be useful without severe adverse events.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Anus Neoplasms / pathology. Dacarbazine / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


24. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. Naumann SC, Roos WP, Jöst E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B: Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer; 2009 Jan 27;100(2):322-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
  • Malignant melanomas are highly resistant to chemotherapy.
  • First-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (DTIC) and temozolomide (TMZ) and the chloroethylating agents BCNU and fotemustine.
  • Here, we determined the mode of cell death in 11 melanoma cell lines upon exposure to TMZ and fotemustine.
  • We show for the first time that TMZ induces apoptosis in melanoma cells, using therapeutic doses.
  • MGMT inactivation by O(6)-benzylguanine sensitized all melanoma cell lines expressing MGMT to TMZ and fotemustine-induced apoptosis, and MGMT transfection attenuated the apoptotic response.
  • This supports that O(6)-alkylguanines are critical lesions involved in the initiation of programmed melanoma cell death.
  • Although these data indicate that methylating drug resistance of melanoma cells can be acquired by down-regulation of mismatch repair, a correlation between MSH2 and MSH6 expression in the different lines and TMZ sensitivity was not found.
  • Apoptosis in melanoma cells induced by TMZ and fotemustine was accompanied by double-strand break (DSB) formation (as determined by H2AX phosphorylation) and caspase-3 and -7 activation as well as PARP cleavage.
  • Melanoma lines expressing p53 wild-type were more resistant to TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with TMZ.
  • Overall, the findings are in line with the model that in melanoma cells TMZ-induced O(6)-methylguanine triggers the apoptotic (and necrotic) pathway through DSBs, whereas for chloroethylating agents apoptosis is triggered in a more complex manner.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. DNA Breaks, Double-Stranded / drug effects. DNA Mismatch Repair / drug effects. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Melanoma / pathology. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):661-8 [12538819.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):816-23 [12970393.001]
  • [Cites] Mutat Res. 2003 Nov;544(2-3):167-72 [14644318.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):359-67 [14724564.001]
  • [Cites] Mol Cell. 2004 Apr 9;14(1):105-16 [15068807.001]
  • [Cites] Oncogene. 2004 May 20;23(23):4060-7 [15048078.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1331-44 [15175264.001]
  • [Cites] Mol Pharmacol. 2004 Sep;66(3):478-91 [15322239.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):3106-10 [241485.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Jul;76(7):3116-20 [91164.001]
  • [Cites] Cancer Res. 1982 Aug;42(8):3102-5 [7093954.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3384-7 [3034412.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1857-67 [1657427.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1503-7 [1394831.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):321-6 [7729942.001]
  • [Cites] J Immunol Methods. 1995 Jul 17;184(1):39-51 [7622868.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1281-4 [7652577.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5375-9 [8968088.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):889-96 [9163672.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] Mutat Res. 1997 Nov 28;381(2):227-41 [9434879.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • [Cites] Carcinogenesis. 1998 Feb;19(2):369-72 [9498291.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1199-202 [9820180.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):744-50 [10048977.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):583-92 [9989808.001]
  • [Cites] Cell Growth Differ. 1999 Mar;10(3):163-71 [10099830.001]
  • [Cites] Int J Biol Markers. 2005 Jan-Mar;20(1):65-8 [15832775.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19166-76 [15753095.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8 [16247014.001]
  • [Cites] Mol Cell. 2006 May 19;22(4):501-10 [16713580.001]
  • [Cites] Trends Mol Med. 2006 Sep;12(9):440-50 [16899408.001]
  • [Cites] Melanoma Res. 2006 Dec;16(6):527-35 [17119454.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):443-51 [17203227.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):186-97 [16819506.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2632-42 [17363583.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):784-90 [17450523.001]
  • [Cites] Cell Death Differ. 2007 Aug;14(8):1422-32 [17464330.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1079-99 [17485253.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1225-33 [17968428.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3342-55 [18079180.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11886-95 [18089819.001]
  • [Cites] Melanoma Res. 2008 Apr;18(2):147-51 [18337652.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 May 15;229(1):20-32 [18289623.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2299-304 [18467721.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):293-8 [17909803.001]
  • [Cites] DNA Repair (Amst). 2009 Jan 1;8(1):72-86 [18840549.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):741-8 [10810349.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5815-24 [11059778.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36256-62 [10954713.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1015-9 [12168066.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):123-9 [11279615.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):335-42 [12170182.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):413-26 [12407507.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1517-23 [14562026.001]
  • (PMID = 19127257.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / COL11A2 protein, human; 0 / Collagen Type XI; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9HW64Q8G6G / Everolimus; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 3.4.22.- / Caspases; EC 6.5.1.- / DNA Repair Enzymes; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2634706
  •  go-up   go-down


26. Kawano N, Tashiro M, Taguchi M, Kihara Y, Yoshikawa I, Syukuwa K, Yamasaki M, Kume K, Otsuki M: [Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma]. Nihon Shokakibyo Gakkai Zasshi; 2008 Nov;105(11):1627-33
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
  • A 73-year-old man, who was diagnosed as having advanced anorectal malignant melanoma (Stage IV), was treated with combination chemotherapy using dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta.
  • After the first course of chemotherapy, rectal tumor was decreased in size with less anal pain and liver tumor was disappeared.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Rectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987448.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 0S726V972K / Nimustine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Ishizone S, Koide N, Karasawa F, Akita N, Muranaka F, Uhara H, Miyagawa S: Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. Int J Colorectal Dis; 2008 Dec;23(12):1257-62
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases.
  • INTRODUCTION: Anorectal malignant melanoma (AMM) is a relatively rare disease.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Palliative Care. Rectum / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):1012-7 [17122627.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):85-8 [1642415.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Am Surg. 2006 Oct;72(10):917-20 [17058735.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10 ):1412-5; discussion 1415-7 [12394445.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • (PMID = 18633625.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Akaraviputh T, Arunakul S, Lohsiriwat V, Iramaneerat C, Trakarnsanga A: Surgery for gastrointestinal malignant melanoma: experience from surgical training center. World J Gastroenterol; 2010 Feb 14;16(6):745-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for gastrointestinal malignant melanoma: experience from surgical training center.
  • AIM: To characterize clinical features, surgery, outcome, and survival of malignant melanoma (MM) of the gastrointestinal (GI) tract in a surgical training center in Bangkok, Thailand.
  • RESULTS: Fourteen patients had GI involvement either in a metastatic form or as a primary melanoma.
  • Seven patients had primary melanomas of the anal canal, stomach and the sigmoid colon (5, 1 and 1 cases, respectively).
  • Six patients had distant metastatic lesions at the time of diagnosis, which made curative resection an inappropriate choice.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Melanoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] Clin Nucl Med. 2009 Jul;34(7):483-5 [19542966.001]
  • [Cites] J Med Assoc Thai. 1978 Apr;61(4):210-6 [650113.001]
  • [Cites] Br J Cancer. 1979 Aug;40(2):185-93 [475965.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):60-1 [1689196.001]
  • [Cites] Ann Surg Oncol. 1999 Mar;6(2):155-60 [10082040.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Cancer. 1964 Oct;17:1323-39 [14236766.001]
  • [Cites] J Med Assoc Thai. 2005 Aug;88(8):1128-33 [16404844.001]
  • [Cites] Mayo Clin Proc. 2006 Apr;81(4):511-6 [16610571.001]
  • [Cites] Am J Surg. 2008 Sep;196(3):e1-2 [18513686.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E6-7 [18278714.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E30-1 [18278719.001]
  • [Cites] Int J Colorectal Dis. 2008 Dec;23(12):1257-62 [18633625.001]
  • [Cites] Dig Liver Dis. 2009 Feb;41(2):169 [18619931.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):313-9 [18590949.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Apr;24(4):697 [19368636.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):516-21 [19410196.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • (PMID = 20135724.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2817064
  •  go-up   go-down


29. Freudlsperger C, Schumacher U, Reinert S, Hoffmann J: The Critical Role of PPARgamma in Human Malignant Melanoma. PPAR Res; 2008;2008:503797
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Critical Role of PPARgamma in Human Malignant Melanoma.
  • The past 30 years have only seen slight improvement in melanoma therapy.
  • Part of the reason for this treatment failure is the broad chemoresistance of melanoma, which is due to an altered survival capacity and an inactivation of apoptotic pathways.
  • Several targetable pathways, responsible for this survival/apoptosis resistance in melanoma, have been described and current research has focused on mechanism inactivating these pathways.
  • However, only a few studies have focused on the effects of PPARgamma agonists in melanoma, showing conflicting results.
  • The use of PPARgamma agonists in melanoma therapy has to be carefully weighted against considerable, undesirable side effects, as their mode of action is not fully understood and even pro-proliferative effects have been described.
  • In the current review, we discuss the role of PPARs, in particular PPARgamma in melanoma and their potential role as a molecular target for melanoma therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 13;270(2):400-5 [10753637.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):645-50 [2129546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9 [10781090.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2573-81 [10873114.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):330-9 [10935488.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5558-64 [11034103.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):29-41 [11237521.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):702-12 [11348458.001]
  • [Cites] J Investig Med. 2001 Sep;49(5):413-20 [11523697.001]
  • [Cites] Lancet Oncol. 2001 Apr;2(4):205-11 [11905765.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Invest Dermatol. 2002 Sep;119(3):576-82 [12230498.001]
  • [Cites] Melanoma Res. 2003 Oct;13(5):447-56 [14512786.001]
  • [Cites] Lab Invest. 2003 Oct;83(10):1529-39 [14563954.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Br J Dermatol. 2004 Mar;150(3):462-8 [15030328.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4912-8 [15256463.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Curr Treat Options Oncol. 2005 May;6(3):185-93 [15869730.001]
  • [Cites] Cancer Lett. 2006 May 8;236(1):133-41 [15979236.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):8-15 [16038868.001]
  • [Cites] Arch Dermatol Res. 2006 Apr;297(10):472-6 [16474974.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):430-7 [16505118.001]
  • [Cites] Anticancer Drugs. 2006 Mar;17(3):325-32 [16520661.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):12953-6 [7768881.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Nov;51(3-4):157-66 [7981125.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):354-66 [8536636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3344-52 [9699665.001]
  • [Cites] J Invest Dermatol. 1998 Dec;111(6):1116-21 [9856826.001]
  • [Cites] Exp Dermatol. 2007 Feb;16(2):118-23 [17222225.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):207-13 [17352234.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1800-4 [10766161.001]
  • (PMID = 18483619.001).
  • [ISSN] 1687-4757
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2377344
  •  go-up   go-down


30. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Griendling K, Martínez-Diez M, Cuezva JM, Arbiser JL: Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest; 2007 Mar;117(3):719-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.
  • Melanoma is the cancer with the highest increase in incidence, and transformation of radial growth to vertical growth (i.e., noninvasive to invasive) melanoma is required for invasive disease and metastasis.
  • We have previously shown that p42/p44 MAP kinase is activated in radial growth melanoma, suggesting that further signaling events are required for vertical growth melanoma.
  • Akt, a signaling molecule downstream of PI3K, was introduced into the radial growth WM35 melanoma in order to test whether Akt overexpression is sufficient to accomplish this transformation.
  • We demonstrated that Akt was associated with malignant transformation of melanoma through at least 2 mechanisms.
  • Targeting Akt and ROS may be of therapeutic importance in treatment of advanced melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 2002 Apr;33(4):206-18 [11933074.001]
  • [Cites] Mol Med. 2002 Jan;8(1):1-8 [11984000.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jun;282(6):C1212-24 [11997235.001]
  • [Cites] Methods Mol Biol. 2002;189:67-73 [12094595.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):365-77 [9387097.001]
  • [Cites] Oncogene. 1998 Jan 29;16(4):523-31 [9484842.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1435-42 [9811334.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] EMBO J. 1999 Apr 1;18(7):1824-31 [10202146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4820-5 [10220377.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1197-202 [10353757.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):79-82 [10485709.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):5-7 [12150818.001]
  • [Cites] J Neurosci. 2002 Aug 15;22(16):7006-15 [12177198.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):643-50 [12208865.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6674-81 [12438266.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3728-33 [12473582.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7335-42 [12499277.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9790-5 [12514183.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12361-6 [12517744.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7315-28 [14517300.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):730-40 [14701745.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):984-91 [14706639.001]
  • [Cites] J Inherit Metab Dis. 2003;26(7):647-58 [14707513.001]
  • [Cites] J Neurochem. 2003 Dec;87(6):1427-35 [14713298.001]
  • [Cites] Pigment Cell Res. 2004 Feb;17(1):74-83 [14717848.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):337-41 [15009714.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1157-63 [14963017.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):1296-302 [15268862.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7002-10 [15466193.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):997-1002 [15496926.001]
  • [Cites] Z Naturforsch B. 1970 Mar;25(3):332-3 [4392802.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Pediatr Res. 1982 Aug;16(8):632-7 [6287402.001]
  • [Cites] Free Radic Res Commun. 1988;5(2):67-75 [2463958.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Biochemistry. 1992 Sep 8;31(35):8300-6 [1525167.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):819-30 [15574336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Clin Chem. 2005 Feb;51(2):305-11 [15590750.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1473-82 [15735123.001]
  • [Cites] FEBS Lett. 2000 Jun 30;476(1-2):52-4 [10878249.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8010-4 [10869423.001]
  • [Cites] J Mol Biol. 2000 Sep 8;302(1):205-17 [10964570.001]
  • [Cites] Trends Biochem Sci. 2000 Oct;25(10):459-61 [11050424.001]
  • [Cites] Nat Neurosci. 2000 Dec;3(12):1301-6 [11100151.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):207-11 [11196646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5550-5 [11331784.001]
  • [Cites] Hum Genet. 2001 Jul;109(1):33-9 [11479733.001]
  • [Cites] Antioxid Redox Signal. 2001 Aug;3(4):697-709 [11554455.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20 [11805326.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):142-50 [11905805.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6282-93 [16024630.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1045-8 [16007689.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Cancer Cell. 2005 Dec;8(6):443-54 [16338658.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D247-51 [16381856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s [16609049.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] Science. 2006 Jul 28;313(5786):521-2 [16809487.001]
  • [Cites] Melanoma Res. 2006 Dec;16(6):471-8 [17119447.001]
  • [Cites] Blood. 2007 Jan 15;109(2):560-5 [16990598.001]
  • (PMID = 17318262.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA27502; United States / NIAMS NIH HHS / AR / R01 AR02030; United States / NCI NIH HHS / CA / CA59327; United States / NCI NIH HHS / CA / P01 CA059327; United States / NCI NIH HHS / CA / P01 CA027502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; EC 1.6.- / Nox4 protein, rat; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1797605
  •  go-up   go-down


31. Gökaslan H, Sişmanoğlu A, Pekin T, Kaya H, Ceyhan N: Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol; 2005 Aug 1;121(2):243-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the vagina: a case report and review of the current treatment options.
  • A case with primary malignant melanoma located in the posterior lower third of the vagina was encountered and treated by surgery, postoperative immunotherapy and chemotherapy.
  • The tumor was close to the anal sphincter and posterior exenteration was done to achieve tumor-free surgical margins.
  • We focused on the treatment options and the possible complication that may arise during the treatment of the primary malignant melanoma of the vagina.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054970.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 25
  •  go-up   go-down


32. Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, Kanazawa Y, Yamada T, Oaki Y, Tajiri T: Case of rectal malignant melanoma showing immunohistochemical variability in a tumor. J Nippon Med Sch; 2007 Oct;74(5):377-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of rectal malignant melanoma showing immunohistochemical variability in a tumor.
  • We report on a patient with rectal malignant melanoma.
  • The patient was a 40-year-old man who complained of anal bleeding.
  • His grandmother had died of pancreatic cancer and his mother had been operated for rectal cancer.
  • Physical examination revealed a hard mass at the 12 o'clock position, 2 cm from the anal verge.
  • With the diagnosis of neuroendocrine carcinoma of the rectum, abdominoperineal resection was performed.
  • However, the final pathological diagnosis of the surgically resected specimen was malignant amelanotic melanoma of the rectum.
  • As preoperative pathological diagnosis showed rare rectal tumor, we measured the chemosensitivity of the rectal tumor using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to determine the most appropriate chemotherapy regimen for the patient.
  • However, there were no anticancer drugs tested by CD-DST for malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / diagnosis. Neoplasm Proteins / analysis. Proto-Oncogene Proteins c-kit / analysis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, Neoplasm. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Digestive System Surgical Procedures. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Fatal Outcome. Humans. Immunohistochemistry. Interferon-beta / administration & dosage. Male. Melanoma-Specific Antigens. Neoadjuvant Therapy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965534.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 77238-31-4 / Interferon-beta; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


33. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


34. Zhong J, Zhou JN, Xu FP, Shang JQ: [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review]. Ai Zheng; 2006 May;25(5):619-24
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review].
  • BACKGROUND & OBJECTIVE: Anorectal malignant melanoma (AMM) is an aggressive malignant tumor, and its treatment still remains controversial.
  • This study was to summarize our experience on diagnosis and treatment of AMM.
  • METHODS: Clinicopathologic records, including clinical feature, diagnosis, operation patterns, and prognosis, of 22 patients with AMM, treated in Jiangsu Provincial Cancer Hospital from 1977 to 2003, were analyzed retrospectively with literature review.
  • RESULTS: The 22 patients with AMM accounted for 0.04% of all the patients diagnosed as malignant tumors of large bowel simultaneously in our hospital.
  • The most common complaints of AMM patients were hematochezia (86%), anus pain or discomfort (59%), local mass (27%), and so on.
  • The definite pathologic diagnosis rate before surgery was 48%.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / surgery. Melanoma / diagnosis. Melanoma / surgery. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Antigens, Neoplasm / metabolism. Chemotherapy, Adjuvant. Colostomy. Diagnostic Errors. Female. Follow-Up Studies. Hemorrhoids / diagnosis. Humans. Liver Neoplasms / secondary. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Rectum / surgery. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687086.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 13
  •  go-up   go-down


35. Pirenne Y, Bouckaert W, Vangertruyden G: Rectal melanoma--a rare tumour. Acta Chir Belg; 2008 Nov-Dec;108(6):756-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal melanoma--a rare tumour.
  • Malignant rectal melanoma is a rare tumour.
  • Biopsies proved it to be an amelanotic malignant melanoma, as protein S100, melanoma antigen HMB45 and Melan-A expression were found.
  • An abdominoperineal resection was performed as a substantial part of the internal anal sphincter was invaded.
  • Histology confirmed an amelanotic malignant melanoma.
  • With this case we want to illustrate that malignant rectal melanoma can be difficult to diagnose, as patients have non-specific symptoms, and histology may be misleading.
  • One should always check for protein S-100, melanoma antigen HMN-45 and Melan-A expression, as they are strongly suggestive of melanoma.
  • Wide local excision is the preferred procedure when technically feasible, but abdominoperineal resection has to be done if the tumour invades a substantial portion of the anal sphincter or is circumferential.
  • Rectal melanoma has a poor outcome with a 5-year survival rate of between 10-20%.
  • [MeSH-major] Melanoma, Amelanotic / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anal Canal / pathology. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Neoplasm Invasiveness. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241934.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


36. Singer M, Mutch MG: Anal melanoma. Clin Colon Rectal Surg; 2006 May;19(2):78-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma.
  • Anal melanoma is rare and aggressive malignancy.
  • Unlike cutaneous melanoma, anal melanoma has no known risk factors.
  • There are no long-term survivors of stage II or III disease; therefore, early diagnosis and treatment remain crucial.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]
  • [Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]
  • [Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]
  • [Cites] Surg Today. 2001;31(6):527-9 [11428607.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]
  • [Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]
  • [Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Surg Today. 1997;27(8):753-6 [9306593.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]
  • [Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • (PMID = 20011314.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780102
  • [Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision
  •  go-up   go-down


37. Balachandra B, Marcus V, Jass JR: Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. Histopathology; 2007 Jan;50(1):163-74
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist.
  • Poorly differentiated malignancies affecting the anal canal are uncommon but pose diagnostic difficulties because of the wide range of normal cell types that may occur within a limited anatomical region.
  • The range of lesions that may present as poorly differentiated tumours includes squamous cell carcinoma, adenocarcinoma, small and large cell neuroendocrine carcinoma, neuroendocrine carcinoma expressing epithelial cytokeratins and other patterns of mixed differentiation, undifferentiated carcinoma, malignant melanoma, lymphoma and secondary tumours.
  • This review discusses the differential diagnosis of these neoplasms with the aid of short illustrative case studies.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Lymphoma / pathology. Male. Melanoma / pathology. Middle Aged. Pathology, Surgical / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204029.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 72
  •  go-up   go-down


38. Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jordá L, Estrela JM: Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia; 2005 Jan;7(1):37-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma.
  • Inhibition of cancer growth by resveratrol (trans-3,5,4'-trihydroxystilbene; RESV), a phytoalexin present in many plant species, is limited by its low bioavailability.
  • In vitro growth of highly malignant B16 melanoma F10 cells (B16M-F10) is inhibited (56%) by short-time exposure (60 min/day) to PTER (40 microm) and QUER (20 microm) (approximate mean values of plasma concentrations measured within the first hour after intravenous administration of 20 mg/kg each polyphenol).
  • Our findings demonstrate that the association of PTER and QUER inhibits metastatic melanoma growth and extends host survival.
  • [MeSH-major] Liver Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Phenols / therapeutic use. Quercetin / therapeutic use. Stilbenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Free Radic Biol Med. 1997;22(7):1203-9 [9098094.001]
  • [Cites] J Cell Physiol. 1998 Mar;174(3):322-30 [9462694.001]
  • [Cites] FEBS Lett. 1998 Jan 16;421(3):277-9 [9468322.001]
  • [Cites] J Nat Prod. 1998 Mar;61(3):362-6 [9544566.001]
  • [Cites] Hepatology. 1998 May;27(5):1249-56 [9581678.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1423-9 [9665419.001]
  • [Cites] Blood. 1998 Aug 1;92(3):996-1002 [9680369.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21875-82 [9705326.001]
  • [Cites] Nutr Rev. 1998 Nov;56(11):317-33 [9838798.001]
  • [Cites] Life Sci. 1999;64(21):1869-76 [10353585.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2596-601 [10363980.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13244-51 [10529197.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] J Pathol. 2000 Feb;190(3):310-29 [10685065.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):567-74 [10845555.001]
  • [Cites] Altern Med Rev. 2000 Jun;5(3):196-208 [10869101.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1619-22 [10910967.001]
  • [Cites] Free Radic Biol Med. 2000 Dec 15;29(12):1234-43 [11118813.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1604-10 [11245472.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1205-15 [11322924.001]
  • [Cites] Annu Rev Nutr. 2001;21:381-406 [11375442.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22586-94 [11316812.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1613-5 [11427503.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25775-82 [11313348.001]
  • [Cites] Clin Exp Metastasis. 2000;18(5):415-21 [11467774.001]
  • [Cites] Adv Exp Med Biol. 2001;492:159-82 [11480664.001]
  • [Cites] Cancer Lett. 2001 Sep 28;171(1):11-6 [11485823.001]
  • [Cites] Cell Physiol Biochem. 2001;11(4):173-86 [11509825.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 1;31(5):642-50 [11522449.001]
  • [Cites] J Agric Food Chem. 2002 Jun 5;50(12):3453-7 [12033810.001]
  • [Cites] Annu Rev Nutr. 2002;22:19-34 [12055336.001]
  • [Cites] Free Radic Biol Med. 2002 Aug 1;33(3):387-98 [12126761.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):79-87 [12554065.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13888-97 [12578841.001]
  • [Cites] J Cell Biochem. 2003 Aug 1;89(5):1044-55 [12874837.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39591-9 [12881529.001]
  • [Cites] FASEB J. 2003 Nov;17(14):1975-85 [14597667.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2339-41 [14563682.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):829-37 [15019968.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):838-49 [15019969.001]
  • [Cites] J Theor Biol. 1985 Jun 7;114(3):413-31 [4021503.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1247-54 [3486997.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Jpn J Cancer Res. 1989 Sep;80(9):818-21 [2513297.001]
  • [Cites] Anal Chem. 1989 Dec 15;61(24):2715-8 [2619057.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6676-81 [1423313.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3233-6 [7515767.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):414-9 [7529137.001]
  • [Cites] Biochem Soc Symp. 1995;61:1-31 [8660387.001]
  • [Cites] Ann Intern Med. 1996 Sep 1;125(5):384-9 [8702089.001]
  • (PMID = 15736313.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alpha4beta1; 0 / Nitrates; 0 / Nitrites; 0 / Phenols; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Vascular Cell Adhesion Molecule-1; 537-42-8 / pterostilbene; 9IKM0I5T1E / Quercetin; BBX060AN9V / Hydrogen Peroxide
  • [Other-IDs] NLM/ PMC1490314
  •  go-up   go-down


39. Sayari S, Moussi A, Bel Haj Salah R, Gherib SB, Haouet K, Zaouche A: Primary anorectal melanoma: a case report. Tunis Med; 2010 Jun;88(6):430-2
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anorectal melanoma: a case report.
  • BACKGROUND: Anorectal melanoma is a rare but highly lethal malignancy.
  • AIM: The aim of this study was to report a case concerning diagnostic and management of Anorectal melanoma.
  • Rectal examination revealed a tender mass arising from the 5 o'clock position of the anal canal that bled on touch.
  • A provisional diagnosis of rectal polyp was made and it was removed by local excision under general anaesthesia.
  • Histopathologic examination reported it as an anorectal malignant melanoma.
  • CONCLUSION: With this case we want to illustrate that malignant melanoma can be difficult to diagnose, as patients have non-specific symptoms and histology may be misleading.
  • Abdominoperineal resection has to be done only in the case of large tumors or when the anal sphincter is involved.
  • [MeSH-major] Melanoma. Rectal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517856.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


40. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer; 2007 Jul 15;121(2):257-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
  • Activating mutations in either BRAF or NRAS are seen in a significant number of malignant melanomas, but their incidence appears to be dependent to ultraviolet light exposure.
  • More recently, activating KIT mutations have been described in rare cases of metastatic melanoma, without further reference to their clinical phenotypes.
  • In this study, we investigated a group of anal melanomas for the presence of BRAF, NRAS, KIT and PDGFRA mutations.
  • No BRAF or PDGFRA mutations were identified in either KIT positive or negative anal melanomas.
  • These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17372901.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NIDDK NIH HHS / DK / HL/DK55748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RBZ1571X5H / Dasatinib
  •  go-up   go-down


41. Klose A, Zigrino P, Dennhöfer R, Mauch C, Hunzelmann N: Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells. Anal Biochem; 2006 Jun 1;353(1):57-62
Hazardous Substances Data Bank. L-Leucine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells.
  • The method was applied to analyze cathepsin activities in cell culture supernatants of the high-invasive melanoma cell line MV3.
  • This novel method permits not only the enzymatic analysis of purified cysteine proteases but also the identification and discrimination of different cathepsin activities in biological fluids, cell lysates, or supernatants, especially of cathepsins B and L, which are closely linked to major inflammatory and malignant processes.
  • [MeSH-major] Cathepsin B / analysis. Cathepsins / analysis. Cysteine Endopeptidases / analysis. Melanoma / chemistry. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. DODECYL SULFATE .
  • Hazardous Substances Data Bank. AMMONIUM LAURYL SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620747.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Cysteine Proteinase Inhibitors; 0 / Dipeptides; 134448-10-5 / N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline; 368GB5141J / Sodium Dodecyl Sulfate; DIQ16UC154 / dodecyl sulfate; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; GMW67QNF9C / Leucine; L5W337AOUR / aloxistatin
  •  go-up   go-down


42. Ma Z, Lui WO, Fire A, Dadras SS: Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens. J Mol Diagn; 2009 Sep;11(5):420-9
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens.
  • A reliable, robust methodology is needed to take full advantage of archived human cancers, especially for those where fresh-frozen tumor banks are unavailable, for example, malignant melanoma.
  • Using a "poison primer" strategy (ie, primer silencing), we blocked the amplification of ribosomal RNA, enabling the successful sequencing of 17 novel and 53 known miRNAs (including small RNAs) from 10-year-old archived normal skin, cutaneous scalp melanoma, and sentinel lymph nodes (both negative and positive for metastasis) excised from a 52-year-old man.
  • [MeSH-major] Formaldehyde / chemistry. Melanoma / pathology. MicroRNAs / genetics. Neoplasms / pathology. Paraffin Embedding / methods. Tissue Fixation / methods

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1999 Nov 15;27(22):4436-43 [10536153.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Diagn Mol Pathol. 2004 Sep;13(3):144-50 [15322425.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Biotechniques. 1993 Mar;14(3):448-53 [7681300.001]
  • [Cites] Pathol Int. 1996 Dec;46(12):997-1004 [9110353.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):155-61 [15782179.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1040-50 [15951835.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):465-73 [16594740.001]
  • [Cites] Nat Genet. 2006 Jun;38 Suppl:S2-7 [16736019.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6031-43 [17616659.001]
  • [Cites] BMC Biotechnol. 2007;7:36 [17603869.001]
  • [Cites] Nucleic Acids Res. 2007;35(19):e130 [17932070.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):203-11 [18403610.001]
  • [Cites] Cell Res. 2008 May;18(5):549-57 [18379589.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6698-706 [18679415.001]
  • [Cites] J Invest Dermatol. 2009 May;129(5):1219-24 [19005486.001]
  • (PMID = 19710399.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC2729839
  •  go-up   go-down


43. Podnos YD, Tsai NC, Smith D, Ellenhorn JD: Factors affecting survival in patients with anal melanoma. Am Surg; 2006 Oct;72(10):917-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting survival in patients with anal melanoma.
  • Anal melanoma is an aggressive tumor with a predilection for early infiltration and distant spread, resulting in poor overall survival.
  • Because anal melanoma is rare, only small case series are reported in the literature, making it difficult to draw conclusions about optimal treatment and outcome.
  • The Surveillance, Epidemiology, and End Results database was used to identify patients with anal melanomas from 1973 to 2001.
  • In addition to demographics, disease extent at presentation, treatment administered, overall survival, and survival by decade of diagnosis were collected.
  • A total of 126 patients with a mean age of 69.2 years was diagnosed with anal melanoma.
  • Neither age at diagnosis, operation performed, nor use of radiation significantly affected survival.
  • Anal melanoma remains an uncommon but lethal disease.
  • [MeSH-major] Anus Neoplasms / mortality. Melanoma / mortality

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058735.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Khaled A, Hammami H, Fazaa B, Kourda N, Kamoun MR, Ben Jilany S, Zoghlami A: Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis. Pathologica; 2009 Jun;101(3):126-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis.
  • BACKGROUND: Anorectal melanoma is a rare and aggressive mucosal cancer.
  • There is usually a delay in diagnosis because about 30% of these cancers are amelanotic and are often mistaken for benign conditions.
  • Herein, we report a case of amelanotic anorectal malignant melanoma with an unusual metastatic deposit in the vulva and also review the literature.
  • CASE REPORT: A 67-year-old woman presented with a history of prolapse of an anal tumour.
  • Histological examination and immunohistochemical staining of all tumours demonstrated malignant melanoma.
  • DISCUSSION: Nine cases of amelanotic malignant melanoma have been reported in the literature.
  • The age at diagnosis ranged from 45 to 77 years.
  • Anorectal melanoma is most common in the rectum, followed by the anal canal.
  • Our case is the tenth case of amelanotic anorectal melanoma and probably corresponds to multiple synchronous primary melanomas of the anorectal region and the vulva, with the possibility that one of the lesions is a primary melanoma and the others are satellite lesions.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma, Amelanotic / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886548.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R: Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer; 2010;10:17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystatin E/M suppresses legumain activity and invasion of human melanoma.
  • In breast cancer, several recent studies have indicated that loss of the cysteine protease inhibitor cystatin E/M leads to increased growth and metastasis.
  • Although cystatin E/M is normally expressed in the skin, its role in cysteine protease regulation and progression of malignant melanoma has not been studied.
  • METHODS: A panel of various non-melanoma and melanoma cell lines was used.
  • Two melanoma cell lines lacking detectable secretion of cystatin E/M were transfected with a cystatin E/M expression plasmid (pCST6), and migration and invasiveness were studied by a Matrigel invasion assay.
  • RESULTS: Cystatin E/M was undetectable in media from all established melanoma cell lines examined, whereas strong immunobands were detected in two of five primary melanoma lines and in two of six lines derived from patients with metastatic disease.
  • Among the four melanoma lines secreting cystatin E/M, the glycosylated form (17 kD) was predominant compared to the non-glycosylated form (14 kD).
  • In the melanoma lines where cystatin E/M was secreted, cystatin C was generally absent or expressed at a very low level.
  • When melanoma cells lacking secretion of cystatin E/M were transfected with pCST6, their intracellular legumain activity was significantly inhibited.
  • Furthermore, invasion was suppressed in cystatin E/M over-expressing melanoma cell lines as measured by the transwell Matrigel assay.
  • CONCLUSIONS: These results suggest that the level of cystatin E/M regulates legumain activity and hence the invasive potential of human melanoma cells.
  • [MeSH-major] Cystatin M / biosynthesis. Cysteine Endopeptidases / biosynthesis. Gene Expression Regulation, Neoplastic. Melanoma / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1626-32 [18754876.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:327-34 [11085925.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):972-82 [11251949.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3493-500 [11309313.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):693-701 [11348457.001]
  • [Cites] Biol Chem. 2001 May;382(5):777-83 [11517930.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 1;1596(1):108-20 [11983426.001]
  • [Cites] Br J Dermatol. 2002 Jul;147(1):87-94 [12100189.001]
  • [Cites] Biol Chem. 2003 Feb;384(2):281-7 [12675521.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2957-64 [12782603.001]
  • [Cites] Oral Oncol. 2003 Sep;39(6):559-68 [12798398.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4069-77 [15205313.001]
  • [Cites] Thromb Haemost. 2004 Jul;92(1):13-22 [15213840.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Histochem Cytochem. 1979 Aug;27(8):1131-9 [90074.001]
  • [Cites] Methods Enzymol. 1981;80 Pt C:535-61 [7043200.001]
  • [Cites] Scand J Clin Lab Invest. 1988 Oct;48(6):573-82 [3064278.001]
  • [Cites] Cancer Metastasis Rev. 1990 Dec;9(4):333-52 [2097084.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15737-44 [8340398.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):301-9 [7519824.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3149-57 [7541714.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Mar;376(3):157-64 [7612192.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):155-61 [7622289.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1996 Jul;114(3):303-11 [8761177.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Feb;377(2):71-86 [8868064.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):682-7 [8938153.001]
  • [Cites] J Biol Chem. 1997 Jan 10;272(2):903-10 [8995380.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):8090-8 [9065484.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):113-23 [9524062.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2733-6 [9661883.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24797-804 [9733783.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):781-90 [10048982.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):19195-203 [10383426.001]
  • [Cites] Anal Biochem. 1999 Sep 10;273(2):278-83 [10469498.001]
  • [Cites] Eur J Cell Biol. 2004 Dec;83(11-12):761-73 [15679120.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2293-9 [15788679.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7066-74 [15905550.001]
  • [Cites] Life Sci. 2006 Jan 18;78(8):898-907 [16150465.001]
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Anal Biochem. 2006 Jun 1;353(1):57-62 [16620747.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15893-9 [16565075.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1233-42 [17043665.001]
  • [Cites] Lab Invest. 2008 Sep;88(9):910-25 [18607344.001]
  • (PMID = 20074384.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Cystatin M; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cysteine Proteases; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.34 / asparaginylendopeptidase
  • [Other-IDs] NLM/ PMC2822816
  •  go-up   go-down


46. Haddow J, Muthapati D, Arshad I, Gupta M, Agarwal P: Multiple bilateral choroidal metastasis from anal melanoma. Int J Clin Oncol; 2007 Aug;12(4):303-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple bilateral choroidal metastasis from anal melanoma.
  • A 58-year-old Caucasian woman with bleeding per rectum had a melanoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Choroid Neoplasms / secondary. Melanoma / diagnosis. Melanoma / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Ophthalmology. 1997 Aug;104(8):1265-76 [9261313.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1677-84 [8233394.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jun;19(6):726-7 [15151641.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] J Clin Gastroenterol. 1999 Sep;29(2):197-9 [10478887.001]
  • [Cites] Eur J Cancer Care (Engl). 1998 Sep;7(3):197-200 [9793012.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • (PMID = 17701012.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Walts AE, Bose S: BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma. Mod Pathol; 2009 Feb;22(2):246-51
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma.
  • The differential diagnosis of perineal biopsies can include squamous intraepithelial lesions, extramammary Paget's disease, and melanoma.
  • BD ProEx C is a recently developed immunoassay that targets expression of two genes shown to be associated with cervical cancer.
  • Immunostaining for ProEx C has been validated in cervical cytology and positive staining has also been shown to be strongly associated with human papilloma virus (HPV)-induced cervical and anal intraepithelial neoplasia in biopsies.
  • We observed positive staining for ProEx C in Paget cells in all of 26 cases of Paget's disease irrespective of tissue site (extramammary, mammary) and in melanoma cells in all of 12 cases of primary perineal melanoma with immunostaining in >50% of malignant cells in 73% of Paget disease cases and 43% of perineal melanoma cases.
  • In situ hybridization was negative for low-risk and high-risk HPV subtypes in all Paget and melanoma cases that were tested.
  • Currently neither of these lesions is known to be HPV related although according to the literature the possibility of a role for HPV in melanoma is still unsettled.
  • [MeSH-major] Antigens, Neoplasm / analysis. Anus Neoplasms / enzymology. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Melanoma / enzymology. Nuclear Proteins / analysis. Paget Disease, Extramammary / enzymology. Perineum / pathology. Reagent Kits, Diagnostic. Vaginal Neoplasms / enzymology. Vulvar Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Biopsy. DNA, Viral / isolation & purification. Diagnosis, Differential. Female. Humans. Immunoassay. In Situ Hybridization. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Mucous Membrane / enzymology. Mucous Membrane / pathology. Mucous Membrane / virology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931649.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Cycle Proteins; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


48. Spugnini EP, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Baroni A, Ruocco E, Laieta MT, Montesarchio V, Cassandro R, Citro G, Baldi A: Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In Vivo; 2007 Sep-Oct;21(5):897-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control and distant metastasis after electrochemotherapy of a canine anal melanoma.
  • Canine anal melanoma is an aggressive neoplasm that rapidly leads to constipation in dogs, thus mimicking the behavior of their human counterpart.
  • [MeSH-major] Anus Neoplasms / veterinary. Dog Diseases / drug therapy. Dog Diseases / pathology. Electrochemotherapy. Melanoma / veterinary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019432.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


49. Homsi J, Garrett C: Melanoma of the anal canal: a case series. Dis Colon Rectum; 2007 Jul;50(7):1004-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anal canal: a case series.
  • PURPOSE: Anal melanoma is an uncommon and aggressive cancer.
  • METHODS: The medical records of patients with anal melanoma treated at the H.
  • Lee Moffitt Cancer and Research Institute between 1987 and 2004 were reviewed.
  • Published anal melanoma studies, including more than ten patients with outcome data, also were reviewed.
  • RESULTS: Twelve patients were identified (8 percent of all cancer of the anal canal).
  • Four patients had nodal involvement, and one had bone metastases at the time of diagnosis.
  • Five of the 11 patients without metastatic disease relapsed or died within the first year of diagnosis (4 had local excision and 1 had abdominoperineal resection).
  • CONCLUSIONS: Anorectal melanoma is a rare and challenging disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Digestive System Surgical Procedures / methods. Melanoma. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prevalence. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468984.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Baljinnyam E, Iwatsubo K, Kurotani R, Wang X, Ulucan C, Iwatsubo M, Lagunoff D, Ishikawa Y: Epac increases melanoma cell migration by a heparan sulfate-related mechanism. Am J Physiol Cell Physiol; 2009 Oct;297(4):C802-13
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epac increases melanoma cell migration by a heparan sulfate-related mechanism.
  • Melanoma, the most malignant form of human skin cancer, has a poor prognosis due to its strong metastatic ability.
  • It was recently demonstrated that Epac, an effector molecule of cAMP, is involved in regulating cell migration; however, the role of Epac in melanoma cell migration remains unclear.
  • We thus examined whether Epac regulates cell migration and metastasis of melanoma.
  • Epac activation, by either specific agonist or overexpression of Epac, increased melanoma cell migration.
  • Deletion of endogenous Epac with small interfering RNA decreased basal melanoma cell migration.
  • These data suggested a major role of Epac in melanoma cell migration.
  • Finally, Epac overexpression enhanced lung colonization of melanoma cells in mice.
  • Taken together, these data indicate that Epac regulates melanoma cell migration/metastasis mostly via syndecan-2 translocation and heparan sulfate production.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20435-42 [9252352.001]
  • [Cites] Mol Biol Cell. 2009 Jul;20(13):3012-24 [19403697.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):27998-8003 [9774414.001]
  • [Cites] Nature. 1998 Dec 3;396(6710):474-7 [9853756.001]
  • [Cites] J Cell Biol. 1999 Feb 8;144(3):575-86 [9971750.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55176-86 [15498767.001]
  • [Cites] Ann Med. 2004;36(8):584-95 [15768830.001]
  • [Cites] Science. 2005 Apr 8;308(5719):211-4 [15825222.001]
  • [Cites] Cell Signal. 2005 Dec;17(12):1551-9 [15908181.001]
  • [Cites] Curr Drug Targets. 2005 Sep;6(6):665-82 [16178800.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38276-89 [16172130.001]
  • [Cites] Front Biosci. 2006;11:1244-54 [16368510.001]
  • [Cites] Nat Cell Biol. 2006 Feb;8(2):113-23 [16429128.001]
  • [Cites] Circ Res. 2006 Jun 9;98(11):1398-404 [16675718.001]
  • [Cites] Mol Biosyst. 2005 Oct;1(4):325-31 [16880999.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7880-8 [16912161.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26391-9 [16818493.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):3026-34 [17080198.001]
  • [Cites] Trends Biochem Sci. 2006 Dec;31(12):680-6 [17084085.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1542-52 [16940330.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):795-805 [17192410.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26734-41 [9334259.001]
  • [Cites] J Biol Chem. 1999 Dec 24;274(52):36921-7 [10601245.001]
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] Curr Biol. 2001 Jan 9;11(1):44-9 [11166179.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):165-7 [11457866.001]
  • [Cites] J Neurocytol. 2000 Nov-Dec;29(11-12):889-911 [11466477.001]
  • [Cites] J Cell Sci. 2002 Mar 1;115(Pt 5):963-72 [11870215.001]
  • [Cites] Exp Cell Res. 2002 Apr 1;274(2):235-45 [11900484.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19946-51 [11889131.001]
  • [Cites] Microcirculation. 2003 Apr;10(2):193-203 [12700587.001]
  • [Cites] Matrix Biol. 2003 Mar;22(1):25-33 [12714039.001]
  • [Cites] J Biol Chem. 2003 May 2;278(18):16045-53 [12591930.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1845-52 [15072971.001]
  • [Cites] J Gene Med. 2004 Jul;6(7):769-76 [15241784.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12670-5 [15314230.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40938-45 [15262973.001]
  • [Cites] Int J Cancer. 1986 Sep 15;38(3):405-11 [3017869.001]
  • [Cites] Clin Exp Metastasis. 1989 Jan-Feb;7(1):85-95 [2535682.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7623-33 [1701350.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):423-35 [1867326.001]
  • [Cites] J Cell Sci. 1992 Dec;103 ( Pt 4):1211-4 [1487497.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):172-81 [8548760.001]
  • [Cites] Cell Death Differ. 2007 Sep;14(9):1605-16 [17541428.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1662-72 [17557924.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Nov;293(5):C1498-508 [17804610.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):212-26 [18292776.001]
  • [Cites] Med Image Anal. 2008 Dec;12(6):689-702 [18571462.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 26;384(2):231-5 [19394307.001]
  • [CommentIn] Am J Physiol Cell Physiol. 2009 Oct;297(4):C797-9 [19692651.001]
  • (PMID = 19657062.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM-067773; United States / NHLBI NIH HHS / HL / HL-059139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / RAPGEF3 protein, human; 0 / Tubulin; 149769-25-5 / Syndecan-2; 9050-30-0 / Heparitin Sulfate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.8 / heparitin sulfotransferase
  • [Other-IDs] NLM/ PMC2770742
  •  go-up   go-down


51. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD, Hearing VJ, Gottesman MM: Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A; 2006 Jun 27;103(26):9903-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.
  • Multidrug resistance mechanisms underlying the intractability of malignant melanomas remain largely unknown.
  • Thus, our experiments provide evidence that melanosomes contribute to the refractory properties of melanoma cells by sequestering cytotoxic drugs and increasing melanosome-mediated drug export.
  • Preventing melanosomal sequestration of cytotoxic drugs by inhibiting the functions of melanosomes may have great potential as an approach to improving the chemosensitivity of melanoma cells.
  • [MeSH-major] Antineoplastic Agents / metabolism. Cisplatin / metabolism. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Melanoma / metabolism. Melanosomes / enzymology. Skin Neoplasms / metabolism


52. Bedin V, Adam RL, de Sá BC, Landman G, Metze K: Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC Cancer; 2010;10:260
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma.
  • BACKGROUND: Prognostic factors in malignant melanoma are currently based on clinical data and morphologic examination.
  • We have therefore investigated whether the fractal dimension of nuclear chromatin measured in routine histological preparations of malignant melanomas could be a prognostic factor for survival.
  • METHODS: We examined 71 primary superficial spreading cutaneous melanoma specimens (thickness > or = 1 mm) from patients with a minimum follow up of 5 years.
  • In the multivariate Cox regression, stratified for the presence or absence of metastases at diagnosis, only the Clark level and fractal dimension of the nuclear chromatin were included as independent prognostic factors in the final regression model.
  • So, there is strong evidence that the fractal dimension of the nuclear chromatin texture is a new and promising variable in prognostic models of malignant melanomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromatin / pathology. Chromatin Assembly and Disassembly. Fractals. Image Processing, Computer-Assisted. Melanoma / mortality. Melanoma / pathology. Skin Neoplasms / pathology


53. Jacobs K, Van Gele M, Forsyth R, Brochez L, Vanhoecke B, De Wever O, Bracke M: P-cadherin counteracts myosin II-B function: implications in melanoma progression. Mol Cancer; 2010;9:255
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-cadherin counteracts myosin II-B function: implications in melanoma progression.
  • BACKGROUND: Malignant transformation of melanocytes is frequently attended by a switch in cadherin expression profile as shown for E- and N-cadherin.
  • For P-cadherin, downregulation in metastasizing melanoma has been demonstrated, and over-expression of P-cadherin in melanoma cell lines has been shown to inhibit invasion.
  • The strong invasive and metastatic nature of cutaneous melanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules RESULTS: In this study we performed a microarray analysis to compare the mRNA expression profile of an invasive BLM melanoma cell line (BLM LIE) and the non-invasive P-cadherin over-expression variant (BLM P-cad).
  • Moreover, myosin II-B plays a major role in melanoma migration and invasiveness by retracting the tail during the migratory cycle, as shown by the localization of myosin II-B stress fibers relative to Golgi and the higher levels of phosphorylated myosin light chain.
  • Analysis of P-cadherin and myosin II-B in nodular melanoma sections and in a panel of melanoma cell lines further confirmed that there is an inverse relationship between both molecules.
  • CONCLUSIONS: Therefore, we conclude that P-cadherin counteracts the expression and function of myosin II-B, resulting in the suppression of the invasive and migratory behaviour of BLM melanoma cells.
  • [MeSH-major] Cadherins / metabolism. Melanoma / metabolism. Nonmuscle Myosin Type IIB / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol Nurs. 2003 Feb;19(1):2-11 [12638376.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:207-35 [14570569.001]
  • [Cites] Mol Biol Cell. 2003 Dec;14(12):4745-57 [12960430.001]
  • [Cites] Lab Invest. 1993 Aug;69(2):152-9 [8350597.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):129-37 [8294496.001]
  • [Cites] J Cell Biol. 1996 Feb;132(3):475-85 [8636223.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):123-61 [8814984.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20246-9 [8702756.001]
  • [Cites] J Cell Sci. 1995 Dec;108 ( Pt 12):3661-70 [8719872.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5033-6 [9371498.001]
  • [Cites] Cell Motil Cytoskeleton. 1997;38(4):351-64 [9415377.001]
  • [Cites] J Cell Biol. 1998 Jan 12;140(1):119-29 [9425160.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):188-94 [9627715.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2121-8 [9815605.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):26-33 [10047526.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8309-17 [15548699.001]
  • [Cites] Cell Calcium. 2005 May;37(5):387-93 [15820385.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3092-9 [15833838.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4330-9 [15806148.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):27130-7 [15911622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13652-7 [16174753.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8774-83 [16204047.001]
  • [Cites] J Cell Sci. 2006 Sep 1;119(Pt 17):3561-70 [16895968.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Neuron. 2007 May 24;54(4):502-5 [17521563.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):555-72; quiz 573-6 [17870429.001]
  • [Cites] Breast Cancer Res. 2007;9(5):214 [18001487.001]
  • [Cites] J Invest Dermatol. 2008 Oct;128(10):2474-84 [18401430.001]
  • [Cites] J Cell Biol. 2008 Nov 3;183(3):543-54 [18955554.001]
  • [Cites] Mol Pathol. 1999 Jun;52(3):151-7 [10621837.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 17;1496(1):3-22 [10722873.001]
  • [Cites] J Cell Sci. 2000 May;113 ( Pt 9):1535-42 [10751145.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1515-25 [10793063.001]
  • [Cites] Nat Neurosci. 2000 Jul;3(7):661-9 [10862698.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33305-8 [11457821.001]
  • [Cites] Anal Biochem. 2002 Apr 1;303(1):95-8 [11906156.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3016-23 [12789276.001]
  • (PMID = 20860798.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / RNA, Small Interfering; EC 3.6.1.- / Nonmuscle Myosin Type IIB
  • [Other-IDs] NLM/ PMC2949802
  •  go-up   go-down


54. Ragnarsson-Olding BK, Nilsson PJ, Olding LB, Nilsson BR: Primary ano-rectal malignant melanomas within a population-based national patient series in Sweden during 40 years. Acta Oncol; 2009;48(1):125-31
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ano-rectal malignant melanomas within a population-based national patient series in Sweden during 40 years.
  • PURPOSE: To analyze 251 patients (101 males and 150 females) diagnosed with ano-rectal malignant melanoma (ARMM) reported to the Swedish National Cancer Registry during 1960-1999.
  • 54% of the tumours were primary in the anal canal, 24% engaged the whole ano-rectal unit and 10% were located at the anal verge (11% unknown primary site).
  • Although ARMM were rare in absolute numbers, their density (number of tumours/square unit) was higher than that of cutaneous malignant melanomas (CMM) on average.
  • The majority of ARMM emerged primary in the anal canal and a primary location exclusively in the colonic mucosa of the rectum is questionable.
  • The higher density of ARMM as compared to the average density of CMM tallies with the result of our previous studies on vulvar melanoma and might be instrumental in exploring non-UV light associated factors in melanoma genesis.
  • The concentration of patients with anal squamous cell carcinoma to population-dense urban areas, as previously reported, was not found in cases of ARMM.
  • [MeSH-major] Anus Neoplasms / epidemiology. Melanoma / epidemiology. Rectal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607861.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


55. Sauer CJ, Klaase JM, Gerritsen JJ, Mastboom WJ: [A malignant tumour in the breast is not always primary breast cancer]. Ned Tijdschr Geneeskd; 2005 Apr 2;149(14):729-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A malignant tumour in the breast is not always primary breast cancer].
  • [Transliterated title] Een maligne mammatumor: niet altijd een primair mammacarcinoom.
  • In a 75-year-old woman with a swelling in her left breast, a 39-year-old woman with an anal fissure due to diarrhoea and a 65-year-old woman with chest pain, a mammary tumour was diagnosed that did not originate in mammary tissue.
  • These were a recurrent melanoma, a carcinoma of the thyroid and a B-cell lymphoma, respectively.
  • Breast cancer is one of the most frequently occurring neoplasms in women.
  • Most of these cases concern haematological malignancies and metastases from melanoma and lung cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / secondary. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Melanoma / diagnosis. Melanoma / secondary. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1426; author reply 1426 [15997699.001]
  • (PMID = 15835620.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Chang Y, Stanley RJ, Moss RH, Van Stoecker W: A systematic heuristic approach for feature selection for melanoma discrimination using clinical images. Skin Res Technol; 2005 Aug;11(3):165-78
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic heuristic approach for feature selection for melanoma discrimination using clinical images.
  • BACKGROUND: Numerous features are derived from the asymmetry, border irregularity, color variegation, and diameter of the skin lesion in dermatology for diagnosing malignant melanoma.
  • The feature selection process is applied to 19 shape and color features for a clinical image data set containing 355 malignant melanomas, 125 basal cell carcinomas, 177 dysplastic nevi, 199 nevocellular nevi, 139 seborrheic keratoses, and 45 vascular lesions.
  • Specifically, average test lesion classification error rates for discriminating malignant melanoma from non-melanoma lesions were reduced from 26.6% for 19 features to 23.2% for 13 features over five randomly generated training and test sets.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dermatol. 1999 Jun;38(6):443-6 [10397584.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):207-18 [11174377.001]
  • [Cites] J Biomed Eng. 1992 May;14(3):229-34 [1588780.001]
  • [Cites] Arch Dermatol. 1990 Jun;126(6):763-6 [2189362.001]
  • [Cites] Comput Med Imaging Graph. 1989 Jan-Feb;13(1):31-6 [2924283.001]
  • [Cites] Anal Quant Cytol Histol. 1988 Dec;10(6):405-16 [3064762.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):555-60 [3958271.001]
  • [Cites] CA Cancer J Clin. 1985 May-Jun;35(3):130-51 [3921200.001]
  • [Cites] Arch Dermatol. 1975 Oct;111(10):1291-2 [1190800.001]
  • [Cites] Skin Res Technol. 2003 May;9(2):147-56 [12709133.001]
  • [Cites] Skin Res Technol. 2003 May;9(2):94-104 [12709126.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):573-6 [12459531.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):199-203 [1623495.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Feb;15(1):1-11 [8471104.001]
  • [Cites] J Dermatol. 1994 Jul;21(7):461-4 [8089364.001]
  • [Cites] IEEE Trans Biomed Eng. 1994 Sep;41(9):837-45 [7959811.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):958-64 [7962777.001]
  • [Cites] J Dermatol. 1994 Nov;21(11):885-90 [7852652.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):252-7 [8674000.001]
  • [Cites] J Am Acad Dermatol. 1997 May;36(5 Pt 1):721-6 [9146533.001]
  • [Cites] J Invest Dermatol. 2002 Aug;119(2):471-4 [12190872.001]
  • (PMID = 15998327.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R43 CA101639; United States / NCI NIH HHS / CA / 1R43 CA-101639-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS327059; NLM/ PMC3193077
  •  go-up   go-down


57. Katona TM, Shienbaum AJ, Wyatt LL, Brown GA, Cheng L: Malignant fibrous histiocytoma of the glans penis: a case report. Anal Quant Cytol Histol; 2006 Feb;28(1):39-42
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the glans penis: a case report.
  • BACKGROUND: Malignant fibrous histiocytoma has been regarded as the most common sarcoma of older adults.
  • However, recent opinion regards pleomorphic malignant fibrous histiocytoma as an undifferentiated high grade pleomorphic sarcoma not otherwise classifiable utilizing current techniques available in surgical pathology.
  • Notwithstanding controversy regarding its nomenclature, malignant fibrous histiocytoma involving the penis is exceedingly rare, with only 4 cases previously described, to our knowledge.
  • CONCLUSION: Malignant fibrous histiocytoma remains a diagnosis of exclusion.
  • Therapeutically important entities in the differential diagnosis that must be ruled out include other poorly differentiated sarcomas, sarcomatoid squamous cell carcinoma and desmoplastic melanoma.

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566278.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA: Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle; 2008 Aug;7(15):2392-400
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.
  • To identify C-MYC targets rate-limiting for proliferation of malignant melanoma, we stably inhibited C-MYC in several human metastatic melanoma lines via lentivirus-based shRNAs approximately to the levels detected in normal melanocytes.
  • C-MYC depletion also resulted in reduction in the amounts of deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. shRNA-mediated suppression of TS, IMPDH2 or PRPS2 resulted in the decrease of dNTP pools and retardation of the cell cycle progression of melanoma cells in a manner similar to that of C-MYC-depletion in those cells.
  • Reciprocally, concurrent overexpression of cDNAs for TS, IMPDH2 and PRPS2 delayed proliferative arrest caused by inhibition of C-MYC in melanoma cells.
  • Moreover, all three proteins express at higher levels in cells from several metastatic melanoma lines compared to normal melanocytes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2002 May;9(5):1031-44 [12049739.001]
  • [Cites] Mutat Res. 2002 Feb 20;499(2):197-211 [11827713.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Jun;3(3):163-75 [12769686.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):43893-6 [13679382.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):562-8 [15229481.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):733-7 [15386371.001]
  • [Cites] Cell Cycle. 2004 Aug;3(8):1005-7 [15280655.001]
  • [Cites] Anal Biochem. 1992 Oct;206(1):178-82 [1456431.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5216-24 [8395000.001]
  • [Cites] J Biol Chem. 1993 Dec 25;268(36):27277-85 [8262968.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2527-35 [7739536.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1039-48 [9342182.001]
  • [Cites] Pharmacol Ther. 1997 Oct-Dec;76(1-3):29-43 [9535167.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):220-4 [9988278.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Curr Med Chem. 1999 Jul;6(7):545-60 [10390600.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5321-33 [10508165.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):3875-80 [15736425.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2097-107 [15781619.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6294-304 [16024631.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:33-50 [16620024.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:51-62 [16620025.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:123-43 [16620027.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:145-67 [16620028.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):951-61 [16575405.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6598-605 [16818632.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):313-7 [16935001.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] EMBO Rep. 2007 Jan;8(1):70-6 [17159920.001]
  • [Cites] Oncogene. 2008 Mar 20;27(13):1905-15 [17906696.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5793-800 [12138190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2023-30 [11511533.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):105-13 [11511364.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;69:115-48 [11550793.001]
  • [CommentIn] Cell Cycle. 2008 Aug;7(15):2275-6 [18682683.001]
  • (PMID = 18677108.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083081; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA076581; United States / NCI NIH HHS / CA / R01-CA120244-A1; United States / NCI NIH HHS / CA / R01 CA120244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleotides; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 1.1.1.205 / IMP Dehydrogenase; EC 1.1.1.205 / IMPDH2 protein, human; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.6.1 / Ribose-Phosphate Pyrophosphokinase
  • [Other-IDs] NLM/ NIHMS486377; NLM/ PMC3744895
  •  go-up   go-down


59. Rasmussen MA, Colding-Jørgensen M, Hansen LT, Bro R: Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol; 2010 Apr;69(4):379-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma.
  • METHODS: A multivariate chemometric approach was developed and applied for evaluating clinical laboratory parameters and biomarkers obtained from two clinical trials investigating recombinant human interleukin-21 (rIL-21) in the treatment of patients with malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Interleukins / pharmacology. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Monit Comput. 2004 Aug;18(4):247-52 [15779836.001]
  • [Cites] Pharmacol Ther. 2006 Jan;109(1-2):92-106 [16051371.001]
  • [Cites] Br J Anaesth. 2006 Jul;97(1):64-8 [16707529.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4 Suppl 1):47-54 [17379087.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3630-6 [17575227.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jun;58(6):843-54 [18925392.001]
  • [Cites] Immunology. 2008 Apr;123(4):575-83 [18005035.001]
  • [Cites] Anal Bioanal Chem. 2008 Mar;390(5):1241-51 [18214448.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2034-9 [18347008.001]
  • [Cites] Cancer Immunol Immunother. 2008 Oct;57(10):1439-49 [18286285.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2123-9 [19276257.001]
  • [Cites] Pharmacogenomics. 2007 Jul;8(7):731-41 [18240906.001]
  • (PMID = 20406222.001).
  • [ISSN] 1365-2125
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Interleukins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / interleukin-21
  • [Other-IDs] NLM/ PMC2848411
  •  go-up   go-down


60. Zhang Q, Chen Y, Wang BD, He P, Su YA: Differences in apoptosis and cell cycle distribution between human melanoma cell lines UACC903 and UACC903(+6), before and after UV irradiation. Int J Biol Sci; 2007 Jul 16;3(6):342-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in apoptosis and cell cycle distribution between human melanoma cell lines UACC903 and UACC903(+6), before and after UV irradiation.
  • Introduction of human chromosome 6 into malignant melanoma cell line UACC903 resulted in generation of the chromosome 6-mediated suppressed cell subline UACC903(+6) that displays attenuated growth rate, anchorage-dependency, and reduced tumorigenicity.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1994 Jan;9(1):255-62 [8302587.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jan;7(1):79-88 [17187522.001]
  • [Cites] Methods Cell Biol. 1994;41:15-38 [7861963.001]
  • [Cites] Methods Cell Biol. 1995;46:29-39 [7541886.001]
  • [Cites] J Immunol Methods. 1995 Jul 17;184(1):39-51 [7622868.001]
  • [Cites] Mol Carcinog. 1996 Apr;15(4):284-99 [8634087.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3186-91 [8764103.001]
  • [Cites] Bioessays. 1996 Mar;18(3):221-8 [8867736.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] J Cell Sci. 2007 Jan 15;120(Pt 2):320-9 [17200141.001]
  • [Cites] Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9 [15609471.001]
  • [Cites] Mol Carcinog. 2000 Jun;28(2):119-27 [10900469.001]
  • [Cites] Curr Opin Oncol. 1997 Mar;9(2):205-13 [9161801.001]
  • [Cites] Int J Radiat Biol. 2006 Nov;82(11):781-92 [17148262.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4138-49 [11464280.001]
  • [Cites] Science. 1990 Feb 2;247(4942):568-71 [2300817.001]
  • [Cites] J Immunol. 1992 Apr 1;148(7):2207-16 [1545126.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Biotechniques. 1993 Dec;15(6):1032-40 [8292335.001]
  • [Cites] Anal Biochem. 1994 May 1;218(2):314-9 [8074286.001]
  • (PMID = 17657283.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / NIH-NIDDK-06-925
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC1925258
  •  go-up   go-down


61. Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D'Almeida V, Correa M, Jasiulionis MG: Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia; 2007 Dec;9(12):1111-21
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation.
  • Melanoma cell lines were previously established after submitting the nontumorigenicmelanocyte lineage, melan-a, to cycles of anchorage blockade.

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Respir Med. 2007 Apr;101(4):800-7 [17010595.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):536-45 [17710156.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 [14641084.001]
  • [Cites] J Neurosci Res. 2004 Feb 15;75(4):508-15 [14743434.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2643-8 [15087371.001]
  • [Cites] Exp Cell Res. 2004 May 1;295(2):497-511 [15093747.001]
  • [Cites] Int Immunopharmacol. 2004 Apr;4(4):475-93 [15099526.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27494-501 [15078887.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27816-23 [15105426.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Mutat Res. 1997 Apr;386(2):141-52 [9113115.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):1-3 [9344579.001]
  • [Cites] J Cell Physiol. 1998 Jun;175(3):359-69 [9572481.001]
  • [Cites] Neuroreport. 1998 Oct 26;9(15):3345-8 [9855277.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 30;253(3):571-6 [9918769.001]
  • [Cites] Clin Chem. 1999 Feb;45(2):290-2 [9931056.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9573-80 [10092643.001]
  • [Cites] Pediatrics. 1999 Oct;104(4 Pt 2):1042-5 [10506262.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1900-2 [15467010.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):948-56 [15705895.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):356-63 [15573371.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7540-9 [15574418.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13341-8 [15671018.001]
  • [Cites] Biochemistry (Mosc). 2005 Feb;70(2):215-21 [15807661.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R139-47 [15809266.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):23363-70 [15831492.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):748-60 [16207477.001]
  • [Cites] J Exp Biol. 2004 Aug;207(Pt 18):3221-31 [15299043.001]
  • [Cites] Nucleic Acids Res. 2004;32(14):4100-8 [15302911.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(7):2085-7 [6425826.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):414-8 [3102392.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1261-4 [8108398.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11327-37 [7744770.001]
  • [Cites] Cell Death Differ. 1999 Oct;6(10):969-75 [10556974.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1595-604 [10587350.001]
  • [Cites] Biochemistry. 2000 Feb 8;39(5):1040-7 [10653649.001]
  • [Cites] Med Hypotheses. 2000 Jan;54(1):95-8 [10790734.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):23-30 [10935467.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29318-23 [10884384.001]
  • [Cites] Biochemistry. 2000 Oct 24;39(42):13005-11 [11041866.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):318-26 [11196180.001]
  • [Cites] Mutat Res. 2001 Mar;488(1):65-76 [11223405.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1707-16 [11245487.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):555-62 [11544023.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 15;31(6):799-808 [11557318.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6263-8 [11593437.001]
  • [Cites] J Nutr. 2001 Nov;131(11):2811-8 [11694601.001]
  • [Cites] Circulation. 2001 Nov 20;104(21):2569-75 [11714652.001]
  • [Cites] Cardiovasc Res. 2002 Feb 15;53(3):577-88 [11861028.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):817-26 [11901190.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:433-9 [12505348.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):163-9 [12531868.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):583-93 [12618510.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):14985-95 [12576480.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1359-68 [12757846.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4723-33 [12879017.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3179-85 [12855558.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):41-6 [9011574.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10164-9 [16288000.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):267-71 [16293798.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):231-41 [16611417.001]
  • [Cites] Eur J Pharmacol. 2006 Aug 21;544(1-3):118-25 [16859669.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7833-6 [16912153.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8413-20 [16951151.001]
  • [Cites] Neurochem Res. 2006 Oct;31(10):1205-10 [17004132.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):995-1002 [17217616.001]
  • (PMID = 18084618.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine; 11062-77-4 / Superoxides; 31C4KY9ESH / Nitric Oxide; 9012-36-6 / Sepharose; EC 3.4.21.4 / Trypsin; GAN16C9B8O / Glutathione; K848JZ4886 / Cysteine; V55S2QJN2X / NG-Nitroarginine Methyl Ester; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2134907
  • [Keywords] NOTNLM ; Anoikis / DNA methylation / carcinogenesis / epigenetics / oxidative stress
  •  go-up   go-down


62. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ: Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem; 2008 Jan;56(1):57-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression in normal skin and non-melanoma skin tumors.
  • Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types of cancer and has been shown to facilitate tumorigenesis in vivo.
  • To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]
  • [Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]
  • [Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]
  • [Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]
  • [Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]
  • [Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]
  • [Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]
  • [Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]
  • [Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • (PMID = 17938278.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2323122
  •  go-up   go-down


63. Kiran RP, Rottoli M, Pokala N, Fazio VW: Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. Dis Colon Rectum; 2010 Apr;53(4):402-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database.
  • PURPOSE: Anal melanoma is rare and associated with a poor outcome.
  • This study evaluates survival of patients undergoing surgery for anal melanoma from a prospective, population-based database.
  • METHODS: Characteristics and survival of patients undergoing rectal resection or local excision for anal melanoma of the anus, anal canal, and overlapping region of the rectum from 1982 to 2002 were obtained from the Surveillance, Epidemiology and End Results database and compared.
  • CONCLUSION: Survival of patients with anal melanoma is similar after local excision or rectal resection irrespective of whether patients have localized or regional stage of disease.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305438.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, Kelly K, Merlino G: Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene; 2010 Apr 22;29(16):2449-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous malignant melanoma is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy.
  • NRAS and BRAF mutations are rarely found in the same melanoma, suggesting that they may possess important overlapping oncogenic activities.
  • More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several malignant phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Genet. 2009 May;41(5):544-52 [19282848.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):5-7 [12150818.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2045-57 [12183360.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6724-30 [12438273.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3113-22 [12789288.001]
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):419-25 [12888294.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):800-6 [12856001.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2338-42 [15059882.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):171-83 [15324700.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2503-12 [2188091.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):810-6 [8631302.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3397-402 [9692547.001]
  • [Cites] Anal Biochem. 1999 Jun 1;270(2):207-19 [10334838.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):533-45 [15950903.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7111-20 [16103060.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(2):727-34 [16382162.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):154-60 [16417231.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]
  • [Cites] Cell. 2006 Oct 6;127(1):157-70 [17018283.001]
  • [Cites] Curr Biol. 2006 Dec 19;16(24):2385-94 [17174914.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968-73 [17576930.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3803-13 [17606711.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7538-50 [17709381.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):8003-14 [17875936.001]
  • [Cites] Melanoma Res. 2007 Dec;17(6):410-2 [17992125.001]
  • [Cites] APMIS. 2007 Oct;115(10):1161-76 [18042149.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):133-40 [18219307.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 [18353141.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3364-72 [18227351.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):784-95 [18505964.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Apr;41(4):757-61 [18950730.001]
  • [ErratumIn] Oncogene. 2011 Apr 14;30(15):1850
  • (PMID = 20118982.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA BC008756-22; United States / Intramural NIH HHS / / ZIA BC008756-23; United States / Intramural NIH HHS / / Z99 CA999999; United Kingdom / Wellcome Trust / / 078327; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / ral Guanine Nucleotide Exchange Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS357536; NLM/ PMC3287039
  •  go-up   go-down


65. Enomoto K, Okamoto H, Numata Y, Takemoto H: A simple and rapid assay for heparanase activity using homogeneous time-resolved fluorescence. J Pharm Biomed Anal; 2006 Jun 7;41(3):912-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Degradation of heparan sulfate proteoglycan by heparanase is an important process in tissue invasion by malignant tumor cells and inflammatory cells.
  • Degradation of the substrate by incubation with murine melanoma cell extract was detected by measuring the time-resolved fluorescence after addition of XL665 (cross-linked allophycocyanin, fluorescence acceptor)-labeled streptavidin.
  • [MeSH-major] Glucuronidase / metabolism. Melanoma, Experimental / enzymology. Spectrometry, Fluorescence / methods

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495030.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9050-30-0 / Heparitin Sulfate; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


66. Messadi M, Bessaid A, Taleb-Ahmed A: Extraction of specific parameters for skin tumour classification. J Med Eng Technol; 2009;33(4):288-95
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanomas are the most malignant skin tumours.
  • This type of cancer is increasing rapidly; its related mortality rate is increasing more modestly, and inversely proportional to the thickness of the tumour.
  • Using skin tumour features such as colour, symmetry and border regularity, an attempt is made to determine if the skin tumour is a melanoma or a benign tumour.
  • In this work, we are interested in extracting specific attributes which can be used for computer-aided diagnosis of melanoma, especially among general practitioners.
  • Then, a sequences of transformations is applied to the image to measure a set of attributes (A: asymmetry, B: border, C: colour and D: diameter) which contain sufficient information to differentiate a melanoma from benign lesions.
  • Finally, the various signs of specific lesion (ABCD) are provided to an artificial neural network to differentiate between malignant tumours and benign lesions.
  • [MeSH-major] Image Interpretation, Computer-Assisted / methods. Melanoma / diagnosis. Pattern Recognition, Automated / methods. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1999 Dec;135(12):1459-65 [10606050.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Mar;20(3):233-9 [11341712.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Feb;15(1):1-11 [8471104.001]
  • [Cites] Comput Biol Med. 1997 Nov;27(6):533-43 [9437554.001]
  • [Cites] Med Biol Eng Comput. 2005 Jul;43(4):436-42 [16255424.001]
  • [Cites] Comput Med Imaging Graph. 2007 Sep;31(6):362-73 [17387001.001]
  • (PMID = 19384704.001).
  • [ISSN] 1464-522X
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683694
  •  go-up   go-down


67. Wiltgen M, Gerger A, Wagner C, Bergthaler P, Smolle J: Evaluation of texture features in spatial and frequency domain for automatic discrimination of histologic tissue. Anal Quant Cytol Histol; 2007 Aug;29(4):251-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the applicability of different texture features in automatic discrimination of microscopic views from benign common nevi and malignant melanoma lesions.
  • RESULTS: Features from the histogram and the co-occurrence matrix enable correct classification of 94.7% of nevi elements and 92.6% of melanoma elements in the training set.
  • Discriminant analysis based on the percentage of "malignant elements" showed correct classification of all nevi cases and 95% of melanoma cases.
  • Features derived from the wavelet and Fourier spectrum showed correct results for 88.8% and 79.3% of nevi and 85.6% and 81.5% of melanoma elements, respectively.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879634.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Mittal R, Perakath B, Chase S, Jesudason MR, Nayak S: Transanal excision of anorectal lesions--a single centre experience. Trop Gastroenterol; 2010 Jan-Mar;31(1):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into three groups. (1) Resection for benign disease (2) Curative and (3) Palliative resection for malignant disease.
  • RESULTS: Forty six patients underwent transanal excision, 21 for benign and 25 for malignant disease, 20 with curative and 5 with palliative intent.
  • Seventeen patients with adenocarcinoma, two with melanoma and one with verrucous carcinoma underwent curative resection.
  • Four patients with malignant melanoma and one with adenocarcinoma underwent palliative resection.
  • It offers good palliation of local symptoms in advanced malignant disease.
  • It can be used in a carefully selected group of patients with early rectal cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


69. Ha TW, Han KH, Son DG, Kim SP, Kim DK: Analysis of loss of heterozygosity in Korean patients with keratoacanthoma. J Korean Med Sci; 2005 Apr;20(2):340-3
Genetic Alliance. consumer health - Keratoacanthoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Loss of heterozygosity (LOH) has been established as an important genetic mechanism giving rise to malignant neoplasia.
  • The mechanism of LOH has been shown to cause basal cell carcinoma and malignant melanoma as well as other types of skin cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1997 Feb;133(2):189-93 [9041832.001]
  • [Cites] J Med Genet. 1996 Nov;33(11):962-4 [8950679.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1043-50 [9353177.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):438-40 [9540988.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):882-3 [9681364.001]
  • [Cites] J Med Genet. 1998 Oct;35(10):841-5 [9783709.001]
  • [Cites] Arch Dermatol Res. 1999 Jan;291(1):1-5 [10025721.001]
  • [Cites] Genet Anal. 1999 Dec 15;15(6):229-33 [10609759.001]
  • [Cites] Arch Dermatol. 2000 May;136(5):657-60 [10815860.001]
  • [Cites] J Invest Dermatol. 2002 Dec;119(6):1367-72 [12485441.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):70-2 [12660037.001]
  • [Cites] J Cutan Pathol. 1980 Oct;7(5):318-25 [7430483.001]
  • [Cites] Ann Plast Surg. 1982 Oct;9(4):306-9 [7149561.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jun;39(2):227-32 [2752375.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Dermatol Surg Oncol. 1990 Jun;16(6):564-8 [2355136.001]
  • [Cites] Am J Dermatopathol. 1993 Aug;15(4):332-42; discussion 343-52 [8214391.001]
  • [Cites] J Am Acad Dermatol. 1994 Jan;30(1):1-19; quiz 20-2 [8277007.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):788-9 [7916075.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • [Cites] Am J Dermatopathol. 1995 Aug;17(4):335-8 [8600795.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):649-53 [8605102.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5128-31 [8912845.001]
  • [Cites] Arch Dermatol Res. 1997 Mar;289(4):185-8 [9143733.001]
  • (PMID = 15832014.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2808619
  •  go-up   go-down


70. Rusiecki JA, Patel R, Koutros S, Beane-Freeman L, Landgren O, Bonner MR, Coble J, Lubin J, Blair A, Hoppin JA, Alavanja MC: Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study. Environ Health Perspect; 2009 Apr;117(4):581-6
Hazardous Substances Data Bank. PERMETHRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study.
  • OBJECTIVE: In this study we evaluated the incidence of cancer among pesticide applicators exposed to permethrin in the Agricultural Health Study (AHS).
  • RESULTS: We found no associations between permethrin and all malignant neoplasms combined, or between permethrin and melanoma, non-Hodgkin lymphoma, leukemia, or cancers of the colon, rectum, lung, or prostate.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Mar 1;165(5):683-9 [11874814.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Mar;259(3):150-3 [12003267.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] J Toxicol Environ Health A. 2002 Oct 11;65(19):1419-35 [12396874.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Nov;12(6):418-26 [12415490.001]
  • [Cites] Am J Epidemiol. 2003 May 1;157(9):800-14 [12727674.001]
  • [Cites] J Reprod Dev. 2004 Apr;50(2):245-55 [15118252.001]
  • [Cites] Toxicology. 2004 Oct 15;203(1-3):17-26 [15363578.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1375-82 [15367570.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):876-85 [15496540.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Fundam Appl Toxicol. 1988 Aug;11(2):308-22 [3220209.001]
  • [Cites] J Environ Sci Health B. 1989 Jun;24(3):265-76 [2547861.001]
  • [Cites] Scand J Work Environ Health. 1992 Aug;18(4):209-15 [1411362.001]
  • [Cites] Epidemiology. 1993 Jan;4(1):55-62 [8420582.001]
  • [Cites] Teratog Carcinog Mutagen. 1992;12(6):269-76 [1363965.001]
  • [Cites] Cell Biol Toxicol. 1993 Jul-Sep;9(3):215-21 [8299001.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Mil Med. 1998 May;163(5):324-30 [9597850.001]
  • [Cites] Environ Health Perspect. 1999 Mar;107(3):173-7 [10064545.001]
  • [Cites] Environ Res. 1999 Feb;80(2 Pt 1):172-9 [10092410.001]
  • [Cites] Environ Health Perspect. 2005 Jan;113(1):49-54 [15626647.001]
  • [Cites] Am J Epidemiol. 2005 Jan 15;161(2):121-35 [15632262.001]
  • [Cites] Altern Lab Anim. 2004 Oct;32(4):383-90 [15651923.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:340-5 [16304401.001]
  • [Cites] J Toxicol Environ Health A. 2005 Dec 10;68(23-24):2175-86 [16326432.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jan 15;218(2):186-95 [17188729.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):225-56 [17425504.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):585-98 [17646864.001]
  • [Cites] J Toxicol Environ Health A. 2007 Oct;70(20):1758-71 [17885933.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • (PMID = 19440497.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / Z01 CP010119; United States / NIEHS NIH HHS / ES / Z01 ES049030; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insecticides; 509F88P9SZ / Permethrin
  • [Other-IDs] NLM/ PMC2679602
  • [Keywords] NOTNLM ; agriculture / cancer / multiple myeloma / occupation / permethrin / pesticide applicator / pesticides / pyrethroid
  •  go-up   go-down


71. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer; 2005 Oct 1;104(7):1505-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.
  • The most frequent NADCs were skin carcinomas (basal cell and squamous cell), Hodgkin disease, and anal carcinoma.
  • The results showed that there were higher rates of melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.
  • A low CD4 nadir or CD4 count at diagnosis (< 200 cells/mL) was not predictive of NADCs.
  • Melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals.
  • Most risk factors for the development of NADCs are nonmodifiable; however, the use of HAART appeared to be beneficial in protecting against the development of malignant disease.
  • [MeSH-minor] Adult. Age Distribution. Aged. Analysis of Variance. Cohort Studies. Comorbidity. Female. HIV Infections / diagnosis. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Probability. Prognosis. Retrospective Studies. Risk Factors. Severity of Illness Index. Sex Distribution. Survival Analysis. United States / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Ramalingam G, Gan EY, Kutt-Sing W: Laparoscopic abdominoperineal resection for anorectal melanoma: a case report and review of the literature. Surg Laparosc Endosc Percutan Tech; 2009 Aug;19(4):e149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic abdominoperineal resection for anorectal melanoma: a case report and review of the literature.
  • Anal melanoma is a rare colorectal disease, accounting for 4% of all anal malignancies.
  • Here we report the first case of a patient with anorectal melanoma who was treated laparoscopically.
  • The literature on anorectal melanoma has been reviewed and controversy still surrounds the optimal treatment modality.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692869.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


73. Krafft C, Kirsch M, Beleites C, Schackert G, Salzer R: Methodology for fiber-optic Raman mapping and FTIR imaging of metastases in mouse brains. Anal Bioanal Chem; 2007 Oct;389(4):1133-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases of malignant melanomas were induced by injecting tumor cells into the carotid artery of mice.
  • Possible reasons why metastatic cells of malignant melanomas were not identified in FTIR images are discussed.
  • [MeSH-minor] Animals. Automatic Data Processing. Brain / pathology. Cell Line, Tumor. Cluster Analysis. Female. Humans. Melanoma / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Optical Fibers. Spectroscopy, Fourier Transform Infrared / methods. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639353.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


74. Finger PT, Latkany P, Kurli M, Iacob C: The Finger iridectomy technique: small incision biopsy of anterior segment tumours. Br J Ophthalmol; 2005 Aug;89(8):946-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses included iris naevus, iris stroma, malignant melanoma, melanocytoma, epithelial inclusion cyst, and sarcoid granuloma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy / methods. Female. Humans. Iris Neoplasms / pathology. Male. Melanoma / pathology. Middle Aged. Minimally Invasive Surgical Procedures / methods. Wound Healing

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cataract Refract Surg. 2003 Nov;29(11):2057-9 [14670411.001]
  • [Cites] Trans Pa Acad Ophthalmol Otolaryngol. 1983 Fall;36(2):169-72 [6659037.001]
  • [Cites] Am J Ophthalmol. 2001 Sep;132(3):328-35 [11530044.001]
  • [Cites] Eye (Lond). 2001 Aug;15(Pt 4):541-2 [11767034.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):235-42 [11825801.001]
  • [Cites] Surv Ophthalmol. 2003 Nov-Dec;48(6):569-93 [14609705.001]
  • [Cites] Ophthalmic Surg. 1984 Jan;15(1):34-40 [6700944.001]
  • [Cites] Surv Ophthalmol. 1985 May-Jun;29(6):410-22 [3892741.001]
  • [Cites] Ophthalmology. 1985 Dec;92(12):1763-7 [4088631.001]
  • [Cites] Am J Ophthalmol. 1990 Oct 15;110(4):361-5 [2220969.001]
  • [Cites] Anal Quant Cytol Histol. 1991 Aug;13(4):293-9 [1718300.001]
  • [Cites] Arch Ophthalmol. 1992 Jul;110(7):969-76 [1637283.001]
  • [Cites] Arch Ophthalmol. 1995 Jun;113(6):777-80 [7786221.001]
  • [Cites] Am J Ophthalmol. 1951 Mar;34(3):432-4 [14819160.001]
  • (PMID = 16024840.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772780
  •  go-up   go-down


75. Belli F, Gallino GF, Lo Vullo S, Mariani L, Poiasina E, Leo E: Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano. Eur J Surg Oncol; 2009 Jul;35(7):757-62
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano.
  • AIMS: This study describes the experience of the National Cancer Institute of Milano in the treatment of anorectal melanoma over the last 32 years.
  • However, even when a radical surgery was undergone, the prognosis of patients with anal melanoma remains dismal.
  • CONCLUSION: Prognosis of anal melanoma remains poor.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602790.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Kim JW, Abramson DH: Topical treatment options for conjunctival neoplasms. Clin Ophthalmol; 2008 Sep;2(3):503-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the past ten years, topical agents have been used by investigators to treat various premalignant and malignant lesions of the conjunctiva, such as primary acquired melanosis with atypia, conjunctival melanoma, squamous intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and pagetoid spread of the conjunctiva arising from sebaceous cell carcinoma.
  • In this review, we present specific guidelines for treating both melanocytic and squamous neoplasms of the conjunctiva, utilizing the available data in the literature as well as our own clinical experience at the Memorial Sloan-Kettering Cancer Center.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1997 Jul;81(7):595-8 [9290377.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1263-9 [9097762.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):248-55 [12040282.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):548-52 [11874760.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Int Ophthalmol Clin. 1993 Summer;33(3):25-30 [8407189.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Jun;70(3):289-96 [1636385.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] Trans Am Ophthalmol Soc. 1991;89:285-98; discussion 298-301 [1808811.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Surv Ophthalmol. 1989 May-Jun;33(6):477-90 [2658172.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):31-4 [11801499.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 1994 Apr;101(4):759-62 [8152772.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Br J Ophthalmol. 1994 Jul;78(7):520-8 [7522545.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Arch Ophthalmol. 1994 Jan;112(1):22-3 [8285885.001]
  • [Cites] Ophthalmology. 1989 Feb;96(2):147-66 [2649838.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Am J Ophthalmol. 1986 Jul 15;102(1):87-90 [3728630.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):673-8 [6462625.001]
  • [Cites] Ophthalmic Surg. 1984 Apr;15(4):289-94 [6728400.001]
  • [Cites] Arch Ophthalmol. 1983 May;101(5):782-6 [6847469.001]
  • [Cites] J Urol. 1981 Oct;126(4):461-4 [6793738.001]
  • [Cites] Arch Ophthalmol. 1980 Aug;98(8):1385-9 [7417073.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Am J Ophthalmol. 1979 Jan;87(1):84-6 [434057.001]
  • [Cites] Doc Ophthalmol. 1973 Feb 21;34(1):93-108 [4706112.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 May;88(5):718-9 [15090432.001]
  • [Cites] Br J Ophthalmol. 2004 Jan;88(1):17-8 [14693762.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1012-6 [12750105.001]
  • [Cites] Cornea. 2003 Mar;22(2):114-7 [12605043.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Am J Ophthalmol. 2001 Oct;132(4):576-8 [11589886.001]
  • [Cites] Br J Ophthalmol. 2001 Sep;85(9):1115-9 [11520767.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Oct;21(5):387-96 [10560521.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1108-14 [15940485.001]
  • [Cites] Cornea. 2005 May;24(4):443-8 [15829803.001]
  • [Cites] Cornea. 2005 Apr;24(3):297-300 [15778602.001]
  • [Cites] Am J Ophthalmol. 2005 Feb;139(2):229-34 [15733981.001]
  • [Cites] Arch Ophthalmol. 2005 Jan;123(1):109-13 [15642823.001]
  • [Cites] Am J Ophthalmol. 1963 Apr;55:811-5 [13948673.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • (PMID = 19668748.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2694026
  • [Keywords] NOTNLM ; 5-Fluorouracil / Mitomycin-C / conjunctival neoplasms melanosis / topical therapies
  •  go-up   go-down


77. Berman DM, Wincovitch S, Garfield S, Romeo MJ: Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol; 2005 Nov;58(11):1206-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although nucleic acid derangements are the hallmark of melanocytic dysplasia, the gold standard for its diagnosis remains the microscopic evaluation of haematoxylin and eosin stained slides.
  • RESULTS: When applied to benign naevi, dysplastic naevi, and melanoma, a very strong significant association was seen between lower NAI and malignant potential (p < 0.0001).
  • Interestingly, the NAI for dysplastic naevi is between that of melanoma and most benign naevi, consistent with their intermediate biological behaviour and histological appearance.
  • CONCLUSION: By providing a quantitative measure for melanocytic neoplasia, the NAI may improve the diagnosis of melanocytic lesions and the selection of treatment.
  • [MeSH-major] DNA, Neoplasm / analysis. Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Processing, Computer-Assisted / methods. Melanocytes / pathology. Microscopy, Confocal / methods. Mitotic Index. Nevus, Pigmented / diagnosis. Nevus, Pigmented / genetics. Nevus, Pigmented / pathology. Paraffin Embedding. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):487-94 [9829812.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):419-26 [9816186.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):190-7 [12775980.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3081-6 [12789284.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):764-71 [12920220.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):243-53 [14603721.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):581-6 [14646621.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S65-9 [15243517.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121 Suppl:S3-32 [15298148.001]
  • [Cites] Lancet. 1977 Apr 16;1(8016):864-5 [67377.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] Cancer Res. 1978 Jul;38(7):1893-8 [77721.001]
  • [Cites] Microsc Acta. 1981 Jan;84(1):37-42 [6163065.001]
  • [Cites] Cytometry. 1982 Jan;2(4):212-8 [6173180.001]
  • [Cites] Cytometry. 1982 Jul;3(1):28-35 [6180873.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):722-5 [2408462.001]
  • [Cites] J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 [2808793.001]
  • [Cites] J Cutan Pathol. 1993 Apr;20(2):121-5 [8320355.001]
  • [Cites] Kurume Med J. 1994;41(1):1-13 [7933912.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Cytometry. 1997 Feb 1;27(2):99-105 [9012376.001]
  • [Cites] Histochem Cell Biol. 1997 Apr;107(4):267-78 [9151109.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • (PMID = 16254113.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1770753
  •  go-up   go-down


78. Fradet-Turcotte A, Archambault J: Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther; 2007;12(4):431-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection by human papillomavirus (HPV) is extremely common and associated with the development of benign warts or malignant lesions of the skin and mucosa.
  • Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers.
  • The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers.
  • Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668552.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] ENG
  • [Grant] None / None / / 68885-1; Canada / Canadian Institutes of Health Research / / 68885-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Proteins; 0 / Viral Proteins
  • [Number-of-references] 192
  • [Other-IDs] NLM/ CAMS5300; NLM/ PMC4646640
  •  go-up   go-down


79. Ingold B, Schraml P, Heppner FL, Moch H: Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS One; 2009;4(3):e4775
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The O(6)-methylguanine-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide.
  • Therefore, we assessed MGMT promoter methylation of various brain metastases including those derived from lung (n = 91), breast (n = 72) kidney (n = 49) and from malignant melanomas (n = 113) by methylation-specific polymerase chain reaction (MS-PCR) and MGMT immunoreactivity.
  • The methylation rate was the highest in brain metastases derived from lung carcinomas (46.5%) followed by those from breast carcinoma (28.8%), malignant melanoma (24.7%) and from renal carcinoma (20%).
  • [MeSH-minor] Alkylating Agents / therapeutic use. Breast Neoplasms / pathology. DNA Methylation. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Immunohistochemistry. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Melanoma / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):416-20 [10404096.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):5-14 [16215811.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S54-65; discusssion S1-4 [16237290.001]
  • [Cites] Future Oncol. 2005 Dec;1(6):747-54 [16556052.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jan;61(1):70-8 [16949297.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):580-4 [17234766.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1459-60 [17442986.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1470-5 [17442989.001]
  • [Cites] Histol Histopathol. 2007 Sep;22(9):1005-15 [17523078.001]
  • [Cites] Cancer Immunol Immunother. 2007 Nov;56(11):1723-31 [17410359.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1764-70 [17597110.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Acta Neuropathol. 2008 Feb;115(2):249-59 [17965865.001]
  • [Cites] Brain Pathol. 2008 Oct;18(4):520-32 [18400046.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5036-42 [18711169.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3262-70 [10866320.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1398-409 [11350911.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Aug;50(2):160-2 [12172983.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3644-50 [12202665.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Int J Mol Med. 2004 Jan;13(1):93-8 [14654977.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Mutat Res. 2004 Oct 4;554(1-2):23-32 [15450401.001]
  • [Cites] J Biol Chem. 1980 Nov 25;255(22):10569-71 [7000780.001]
  • [Cites] Mol Cell Biol. 1991 Sep;11(9):4660-8 [1875945.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4648-52 [8062258.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):161-6 [7785768.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Mutat Res. 1996 May 15;363(1):15-25 [8632775.001]
  • [Cites] Carcinogenesis. 1996 Nov;17(11):2329-36 [8968045.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):981-6 [10233835.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):333-40 [15662974.001]
  • (PMID = 19274096.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2652028
  •  go-up   go-down


80. Kong R, Reddy RK, Bhargava R: Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging. Analyst; 2010 Jul;135(7):1569-78
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we apply Fourier transform infrared (FT-IR) spectroscopic imaging to examine an engineered tissue model of melanoma.
  • Second, we introduce malignant melanocytes to simulate tumor formation and growth.
  • The development of this analytical approach combining engineered tissue with spectroscopy, imaging and computation will allow for quality control and standardization in tissue engineering and novel scientific insight in cancer progression.
  • [MeSH-major] Melanoma / chemistry. Skin Neoplasms / chemistry. Spectroscopy, Fourier Transform Infrared / methods. Tissue Engineering

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):189-202 [9551650.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2057-9 [8953032.001]
  • [Cites] Arch Dermatol. 1999 Aug;135(8):913-8 [10456339.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Annu Rev Phys Chem. 2005;56:429-74 [15796707.001]
  • [Cites] ScientificWorldJournal. 2005 Mar 18;5:173-82 [15798877.001]
  • [Cites] Nat Biotechnol. 2005 Apr;23(4):469-74 [15793574.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 5;1724(3):262-9 [15935560.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2308s-2311s [16609050.001]
  • [Cites] Biochim Biophys Acta. 2006 Jul;1758(7):923-33 [16730643.001]
  • [Cites] Analyst. 2006 Aug;131(8):875-85 [17028718.001]
  • [Cites] Anal Bioanal Chem. 2007 Mar;387(5):1591-9 [17160382.001]
  • [Cites] Mayo Clin Proc. 2007 Mar;82(3):364-80 [17352373.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:252-8 [17445214.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):044010 [17867814.001]
  • [Cites] Appl Spectrosc. 2009 May;63(5):512-7 [19470207.001]
  • [Cites] Analyst. 2009 Jun;134(6):1208-14 [19475150.001]
  • [Cites] Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S54-8 [19380232.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034011 [19566304.001]
  • [Cites] Tumour Biol. 2009;30(3):109-20 [19440007.001]
  • [Cites] Int J Cancer. 2009 Oct 15;125(8):1796-804 [19569239.001]
  • [Cites] J R Soc Interface. 2010 Feb 6;7(43):229-58 [19864266.001]
  • [Cites] PLoS One. 2009;4(12):e8461 [20041153.001]
  • [Cites] Analyst. 2009 Aug;134(8):1669-74 [20448936.001]
  • [Cites] Anal Bioanal Chem. 2007 Oct;389(4):1155-69 [17786414.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2006;1:2766-9 [17945738.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Analyst. 2008 Feb;133(2):197-205 [18227942.001]
  • [Cites] Analyst. 2008 Mar;133(3):372-8 [18299752.001]
  • [Cites] Dis Markers. 2008;25(6):323-37 [19208950.001]
  • [Cites] J Biophotonics. 2009 Feb;2(1-2):104-13 [19343689.001]
  • [Cites] Anal Chim Acta. 2009 May 29;642(1-2):246-56 [19427483.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1708-12 [11721053.001]
  • [Cites] Regul Toxicol Pharmacol. 2001 Dec;34(3):234-48 [11754528.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):148-56 [11818022.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):522-36 [12492494.001]
  • [Cites] J Biomed Opt. 2003 Apr;8(2):185-90 [12683844.001]
  • [Cites] Eur J Cell Biol. 2003 Nov;82(11):539-48 [14703010.001]
  • [Cites] J Control Release. 2004 Jun 18;97(2):269-81 [15196754.001]
  • [Cites] Appl Spectrosc. 2004 Aug;58(8):995-1000 [15324507.001]
  • [Cites] Biochim Biophys Acta. 1995 Jan 25;1270(1):1-6 [7827129.001]
  • [Cites] Anal Chem. 1995 Oct 1;67(19):3377-81 [8686889.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):311-20 [8745328.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):203-10 [9551651.001]
  • (PMID = 20498913.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138882; United States / NCI NIH HHS / CA / R01 CA138882-01A1; United States / NCI NIH HHS / CA / R01CA138882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS259193; NLM/ PMC3030988
  •  go-up   go-down


81. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M: Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med; 2005 Mar;2(3):e70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.
  • Most important, this study shows, that [(18)F]Galacto-RGD with PET enables noninvasive quantitative assessment of the alphavbeta3 expression pattern on tumor and endothelial cells in patients with malignant tumors.
  • [MeSH-minor] Animals. Blotting, Western. Carcinoma, Squamous Cell / radionuclide imaging. Humans. Immunohistochemistry. Melanoma / radionuclide imaging. Mice. Neoplasms / blood supply. Neoplasms / pathology. Neovascularization, Pathologic. Positron-Emission Tomography. Sensitivity and Specificity. Skin Neoplasms / radionuclide imaging. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2625-34 [9829725.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):184-9 [15632051.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] Adv Cancer Res. 2000;79:1-38 [10818676.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3056-61 [10955784.001]
  • [Cites] Magn Reson Med. 2000 Sep;44(3):433-9 [10975896.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):326-36 [11216533.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):136-43 [11303882.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 16):94-104 [11706401.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):28-38 [11807604.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):690-7 [11920637.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]
  • [Cites] Cell. 2002 Sep 6;110(5):599-11 [12230977.001]
  • [Cites] Bioconjug Chem. 2002 Sep-Oct;13(5):1021-30 [12236784.001]
  • [Cites] Calcif Tissue Int. 2002 Oct;71(4):293-9 [12154391.001]
  • [Cites] Expert Opin Biol Ther. 2002 Dec;2(8):953-66 [12517273.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):641-6 [12537667.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):203-13 [12741679.001]
  • [Cites] Chemistry. 2003 Jun 16;9(12):2717-25 [12772286.001]
  • [Cites] Q J Nucl Med. 2003 Sep;47(3):189-99 [12897710.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Jun;4(6):741-5 [12901235.001]
  • [Cites] Angiogenesis. 2002;5(4):237-56 [12906317.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5838-43 [14522907.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):228-30 [14693249.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):11-9 [14741566.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Curr Pharm Des. 2004;10(13):1439-55 [15134568.001]
  • [Cites] J Nucl Med. 2004 May;45(5):892-902 [15136641.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1776-83 [15471848.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17703-11 [2447074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23 [1712106.001]
  • [Cites] FEBS Lett. 1991 Oct 7;291(1):50-4 [1718779.001]
  • [Cites] Eur J Immunol. 2004 Jun;34(6):1608-16 [15162430.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):231-44 [15186604.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9 [15118844.001]
  • [Cites] Mol Imaging. 2004 Apr;3(2):96-104 [15296674.001]
  • [Cites] Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 [15380745.001]
  • [Cites] J Clin Invest. 1992 Jun;89(6):2018-22 [1376331.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1188-94 [7515558.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1815-22 [7560073.001]
  • [Cites] Eur J Nucl Med. 1995 Dec;22(12):1420-32 [8586089.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Nat Med. 1998 May;4(5):623-6 [9585240.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3033-40 [10447947.001]
  • (PMID = 15783258.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC1069665
  •  go-up   go-down


82. Lebe B, Pabuççuoglu U, Ozer E: Expression pattern of type IV collagen in sporadic dysplastic melanocytic nevi. Anal Quant Cytol Histol; 2008 Oct;30(5):291-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the expression and distribution pattern of type IV collagen in dysplastic nevi (DN) and to determine whether DN exhibits a morphologic difference from common melanocytic nevi (CMN) and cutaneous malignant melanomas (MM) and therefore can be classified as a separate entity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980161.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV
  •  go-up   go-down


83. Sorensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brünner N, Usher PA: Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem; 2006 Oct;54(10):1075-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All seven VT antibodies specifically immunostained the cytoplasm of islets of Langerhans cells in normal pancreas, epithelial cells of hyperplastic prostate, tumor cells of medullary thyroid carcinoma, and fibroblast-like cells of malignant melanoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 May;80(3-4):495-503 [10408859.001]
  • [Cites] J Neurosci. 1999 Jun 15;19(12):4994-5004 [10366632.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 [15588763.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Tumour Biol. 2005 Mar-Apr;26(2):71-80 [15870512.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6267-75 [10626822.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4292-9 [11106246.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):111-20 [11235986.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):931-7 [11457921.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):156-64 [11801553.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11069-76 [11796725.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):80-8 [12605370.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):767-74 [12639219.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Expert Rev Mol Med. 2003 Sep;5(23):1-39 [14585170.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):263-72 [14603723.001]
  • [Cites] J Biol Chem. 1979 Mar 25;254(6):1938-43 [217874.001]
  • [Cites] J Biol Chem. 1983 Oct 25;258(20):12252-8 [6313647.001]
  • [Cites] J Biol Chem. 1983 Oct 25;258(20):12259-64 [6313648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2407-11 [3010309.001]
  • [Cites] Biochem J. 1986 Sep 15;238(3):677-82 [3099772.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5539-45 [3416307.001]
  • [Cites] Science. 1989 Feb 17;243(4893):947-50 [2465572.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):666-72 [1657796.001]
  • [Cites] J Cell Biol. 1992 Aug;118(3):727-39 [1639854.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):303-9 [8895669.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1255-64 [8918435.001]
  • [Cites] Mod Pathol. 1997 Jan;10(1):47-54 [9021726.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1708-15 [9057654.001]
  • [Cites] J Histochem Cytochem. 1997 Mar;45(3):327-43 [9071315.001]
  • [Cites] Histopathology. 1997 Aug;31(2):150-6 [9279566.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):397-403 [9487122.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1369-72 [9816309.001]
  • [Cites] J Clin Invest. 1998 Dec 1;102(11):2002-10 [9835626.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):733-43 [10360651.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):198-206 [15386409.001]
  • (PMID = 16517973.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Fixatives; 0 / Tissue Inhibitor of Metalloproteinase-1; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC3957804
  •  go-up   go-down


84. Charpentier TH, Thompson LE, Liriano MA, Varney KM, Wilder PT, Pozharski E, Toth EA, Weber DJ: The effects of CapZ peptide (TRTK-12) binding to S100B-Ca2+ as examined by NMR and X-ray crystallography. J Mol Biol; 2010 Mar 12;396(5):1227-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Structure-based drug design is underway to inhibit the S100B-p53 interaction as a strategy for treating malignant melanoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Biochem Biophys Res Commun. 1965 Jun 9;19(6):739-44 [4953930.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Oct;60(Pt 10):1833-9 [15388930.001]
  • [Cites] J Biol Chem. 1970 Dec 25;245(24):6547-52 [5482765.001]
  • [Cites] Methods Enzymol. 1972;26:654-82 [4376581.001]
  • [Cites] J Biol Chem. 1980 Sep 10;255(17):8154-6 [7410354.001]
  • [Cites] Biochemistry. 1986 Jan 14;25(1):68-77 [3513826.001]
  • [Cites] J Biol Chem. 1986 Jun 25;261(18):8204-12 [3722150.001]
  • [Cites] Biochemistry. 1987 Mar 10;26(5):1289-300 [3567171.001]
  • [Cites] Annu Rev Biochem. 1989;58:951-98 [2673026.001]
  • [Cites] Biochemistry. 1990 Sep 18;29(37):8632-42 [1702994.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6103-14 [1676297.001]
  • [Cites] Methods Enzymol. 1994;239:3-79 [7830587.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14651-8 [7540176.001]
  • [Cites] J Magn Reson B. 1995 Jul;108(1):94-8 [7627436.001]
  • [Cites] J Biomol NMR. 1995 Nov;6(3):277-93 [8520220.001]
  • [Cites] J Biomol NMR. 1995 Sep;6(2):171-9 [8589606.001]
  • [Cites] Biochemistry. 1996 Sep 10;35(36):11577-88 [8794737.001]
  • [Cites] Structure. 1996 Sep 15;4(9):1041-52 [8805590.001]
  • [Cites] Protein Sci. 1997 Jul;6(7):1577-82 [9232658.001]
  • [Cites] Biochemistry. 1997 Aug 12;36(32):9674-80 [9245399.001]
  • [Cites] Biochemistry. 1998 Mar 3;37(9):2729-40 [9485423.001]
  • [Cites] Biochemistry. 1998 Feb 17;37(7):1951-60 [9485322.001]
  • [Cites] Structure. 1998 Feb 15;6(2):211-22 [9519411.001]
  • [Cites] Structure. 1998 Feb 15;6(2):233-41 [9519413.001]
  • [Cites] Curr Opin Struct Biol. 1998 Oct;8(5):631-9 [9818269.001]
  • [Cites] Biometals. 1998 Dec;11(4):383-97 [10191501.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10539-44 [10187847.001]
  • [Cites] Protein Sci. 1999 Apr;8(4):800-9 [10211826.001]
  • [Cites] Protein Sci. 1999 Sep;8(9):1743-51 [10493575.001]
  • [Cites] Biochemistry. 1963 Sep-Oct;2:910-9 [14087380.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] Biochemistry. 2005 May 17;44(19):7305-14 [15882069.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):201-14 [16683912.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov;1763(11):1284-97 [17010455.001]
  • [Cites] J Biomol NMR. 2008 Dec;42(4):279-86 [18949447.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):235-42 [10592235.001]
  • [Cites] Nat Struct Biol. 2000 Jul;7(7):570-4 [10876243.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):35037-41 [11454863.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1451-6 [11567159.001]
  • [Cites] Methods Mol Biol. 2002;172:69-80 [11833360.001]
  • [Cites] Biochemistry. 2002 Mar 19;41(11):3637-46 [11888280.001]
  • [Cites] Structure. 2002 Apr;10(4):557-67 [11937060.001]
  • [Cites] Biochemistry. 2002 Apr 30;41(17):5421-8 [11969402.001]
  • [Cites] J Mol Biol. 2002 Dec 13;324(5):1003-14 [12470955.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):6251-7 [12480931.001]
  • [Cites] Microsc Res Tech. 2003 Apr 15;60(6):540-51 [12645002.001]
  • [Cites] J Mol Biol. 2009 Mar 13;386(5):1265-77 [19452629.001]
  • [Cites] Biochemistry. 2003 Dec 16;42(49):14416-26 [14661952.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):34071-7 [15178678.001]
  • [Cites] Methods Mol Biol. 2004;278:313-52 [15318002.001]
  • [Cites] Anal Biochem. 2004 Sep 15;332(2):261-73 [15325294.001]
  • [Cites] J Biol Chem. 1966 Mar 10;241(5):1178-93 [5933875.001]
  • (PMID = 20053360.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] ENG
  • [Databank-accession-numbers] PDB/ 3IQO/ 3IQQ
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM058888-08; United States / NCRR NIH HHS / RR / S10 RR023447; United States / NCI NIH HHS / CA / CA107331-04S1; United States / NCI NIH HHS / CA / CA107331-02; United States / NIGMS NIH HHS / GM / R01 GM058888-11S1; United States / NCI NIH HHS / CA / CA107331-01A3; United States / NIGMS NIH HHS / GM / GM058888-11; United States / NCRR NIH HHS / RR / S10 RR016812; United States / NIGMS NIH HHS / GM / R01 GM058888-11; United States / NCRR NIH HHS / RR / RR015741-01; United States / NIGMS NIH HHS / GM / R01 GM058888-09; United States / NCRR NIH HHS / RR / S10 RR015741-01; United States / NCI NIH HHS / CA / R01 CA107331-03; United States / NCRR NIH HHS / RR / S10 RR023447-01; United States / NCI NIH HHS / CA / CA107331-04; United States / NIGMS NIH HHS / GM / GM058888-10; United States / NCI NIH HHS / CA / R01 CA107331; United States / NIGMS NIH HHS / GM / GM58888; United States / NIGMS NIH HHS / GM / R01 GM058888-10; United States / NCI NIH HHS / CA / CA107331; United States / NIGMS NIH HHS / GM / GM058888-11S1; United States / NCRR NIH HHS / RR / S10 RR016812-01; United States / NIGMS NIH HHS / GM / GM058888-08; United States / NCI NIH HHS / CA / CA107331-03; United States / NCI NIH HHS / CA / R01 CA107331-04; United States / NCRR NIH HHS / RR / RR016812-01; United States / NCI NIH HHS / CA / R01 CA107331-04S1; United States / NCI NIH HHS / CA / R01 CA107331-01A3; United States / NCI NIH HHS / CA / R01 CA107331-02; United States / NCRR NIH HHS / RR / S10 RR015741; United States / NIGMS NIH HHS / GM / GM058888-09; United States / NIGMS NIH HHS / GM / R01 GM058888; United States / NCRR NIH HHS / RR / RR023447-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CapZ Actin Capping Protein; 0 / Multiprotein Complexes; 0 / Nerve Growth Factors; 0 / Oligopeptides; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human; 0 / TRTK-12 peptide; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS177816; NLM/ PMC2843395
  •  go-up   go-down


85. Murrell ZA, Dixon MR, Vargas H, Arnell TD, Kumar R, Stamos MJ: Contemporary indications for and early outcomes of abdominoperineal resection. Am Surg; 2005 Oct;71(10):837-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for operation were primary rectal cancer (n = 31), recurrent rectal cancer (n = 6), intractable Crohn disease (n = 3), anal melanoma (n = 1), cloacogenic cancer (n = 1), squamous cell cancer (n = 1), and gastrointestinal stromal tumor (n = 1).
  • Despite the significant morbidity associated with this surgery, APR may provide beneficial treatment for select cases of low rectal cancer, end-stage inflammatory bowel disease, and anal malignancies.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468531.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. May KM, Vogt A, Bachas LG, Anderson KW: Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor. Anal Bioanal Chem; 2005 Jun;382(4):1010-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor.
  • Vascular endothelial growth factor (VEGF) is a cytokine and endothelial cell (EC) mitogen that has been studied for its role in angiogenesis of malignant tumors.
  • Elevated quantities of VEGF in the serum and plasma of patients have been correlated with the presence of cancer and metastasis.
  • The practical applicability of the biosensor was also established with cultured human melanoma cells WM793 (nonmetastatic) and 1205LU (metastatic).
  • [MeSH-major] Biosensing Techniques / methods. Endothelial Cells / chemistry. Melanoma / diagnosis. Vascular Endothelial Growth Factors / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928947.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


87. Wall SJ, Werner E, Werb Z, DeClerck YA: Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem; 2005 Dec 2;280(48):40187-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During malignant invasion tumor cells establish contact with extracellular matrix proteins, including fibrillar collagen.
  • Here we provide evidence for a direct inhibitory effect of fibrillar collagen on proliferation of human melanoma and fibrosarcoma cells that involves activation of the tyrosine kinase discoidin domain receptor 2 and is independent of effects on cell spreading.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5779-84 [10681566.001]
  • [Cites] J Mol Biol. 2004 Dec 3;344(4):993-1003 [15544808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10026-31 [10944199.001]
  • [Cites] Matrix Biol. 2000 Aug;19(4):319-23 [10963992.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):115-27 [11511365.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1369-78 [11696582.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):4066-77 [11739801.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3606-13 [11723120.001]
  • [Cites] J Cell Biochem. 2002;84(4):759-71 [11835401.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):19206-12 [11884411.001]
  • [Cites] Mol Biol Cell. 1995 Mar;6(3):273-82 [7612963.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24666-9 [7559578.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1069-78 [8978611.001]
  • [Cites] Endocrinology. 1997 Apr;138(4):1642-8 [9075726.001]
  • [Cites] Exp Mol Pathol. 1997;64(3):185-94 [9439483.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):13-23 [9659899.001]
  • [Cites] Trends Cell Biol. 1998 Nov;8(11):437-41 [9854310.001]
  • [Cites] Biochem J. 1999 May 1;339 ( Pt 3):481-8 [10215583.001]
  • [Cites] J Cell Sci. 1999 Aug;112 ( Pt 16):2677-91 [10413676.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1329-40 [12029618.001]
  • [Cites] Int J Oncol. 1998 Jan;12(1):181-6 [9454903.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16761-9 [12611880.001]
  • [Cites] Eur J Pharmacol. 2003 May 16;468(3):159-66 [12754053.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21886-92 [12676963.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):889-90 [12931168.001]
  • [Cites] J Urol. 2003 Nov;170(5):2072-6 [14532856.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1575-85 [15111304.001]
  • [Cites] Anal Biochem. 1980 Feb;102(1):196-202 [7188842.001]
  • [Cites] J Cell Biol. 1982 Apr;93(1):211-6 [7040414.001]
  • [Cites] Science. 1983 Feb 4;219(4584):493-5 [6681676.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] Dev Biol. 1988 Jan;125(1):158-67 [3334715.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):542-8 [2478181.001]
  • [Cites] Exp Eye Res. 1990 Feb;50(2):165-72 [1690142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5888-92 [2165607.001]
  • [Cites] Curr Eye Res. 1991 Jan;10(1):61-74 [2029849.001]
  • [Cites] EMBO J. 1992 Nov;11(11):3941-51 [1396587.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2313-5 [8505213.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5467-73 [7923181.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):249-56 [10806474.001]
  • (PMID = 16186104.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042919; United States / NCI NIH HHS / CA / R01 CA42919; United States / NCI NIH HHS / CA / CA058207-12; United States / NCI NIH HHS / CA / R01 CA98469; United States / NCI NIH HHS / CA / P50 CA058207-12; United States / NCI NIH HHS / CA / CA057621-07; United States / NCI NIH HHS / CA / P50 CA58207; United States / NCI NIH HHS / CA / P50 CA058207; United States / NCI NIH HHS / CA / R01 CA057621-07; United States / NCI NIH HHS / CA / R01 CA098469; United States / NCI NIH HHS / CA / R01 CA057621; United States / NCI NIH HHS / CA / R01 CA57621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Receptors, Mitogen; 63231-63-0 / RNA; 9007-34-5 / Collagen; DH2M523P0H / Genistein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  • [Other-IDs] NLM/ NIHMS152810; NLM/ PMC2768768
  •  go-up   go-down


88. Berretta R, Moscato P: Cancer biomarker discovery: the entropic hallmark. PLoS One; 2010;5(8):e12262

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarker discovery: the entropic hallmark.
  • BACKGROUND: It is a commonly accepted belief that cancer cells modify their transcriptional state during the progression of the disease.
  • We propose that the progression of cancer cells towards malignant phenotypes can be efficiently tracked using high-throughput technologies that follow the gradual changes observed in the gene expression profiles by employing Shannon's mathematical theory of communication.
  • Methods based on Information Theory can then quantify the divergence of cancer cells' transcriptional profiles from those of normally appearing cells of the originating tissues.
  • METHODOLOGY/PRINCIPAL FINDINGS: Using melanoma and prostate cancer datasets we illustrate how it is possible to employ Shannon Entropy and the Jensen-Shannon divergence to trace the transcriptional changes progression of the disease.
  • We establish how the variations of these two measures correlate with established biomarkers of cancer progression.
  • The Information Theory measures allow us to identify novel biomarkers for both progressive and relatively more sudden transcriptional changes leading to malignant phenotypes.
  • At the same time, the methodology was able to validate a large number of genes and processes that seem to be implicated in the progression of melanoma and prostate cancer.
  • CONCLUSIONS/SIGNIFICANCE: We thus present a quantitative guiding rule, a new unifying hallmark of cancer: the cancer cell's transcriptome changes lead to measurable observed transitions of Normalized Shannon Entropy values (as measured by high-throughput technologies).
  • At the same time, tumor cells increment their divergence from the normal tissue profile increasing their disorder via creation of states that we might not directly measure.
  • This unifying hallmark allows, via the the Jensen-Shannon divergence, to identify the arrow of time of the processes from the gene expression profiles, and helps to map the phenotypical and molecular hallmarks of specific cancer subtypes.
  • [MeSH-minor] Animals. Gene Expression Profiling. Genes, Neoplasm / genetics. Humans. Male. Melanoma / genetics. Melanoma / metabolism. Melanoma / pathology. Mice. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Med Liege. 1999 Nov;54(11):867-74 [10667046.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):743-8 [10684866.001]
  • [Cites] Cytogenet Cell Genet. 1999;87(3-4):286-90 [10702697.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F13-28 [10644652.001]
  • [Cites] J Exp Med. 2000 Mar 20;191(6):1005-16 [10727462.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9308-13 [10734072.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):209-22 [10747098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4386-91 [10737773.001]
  • [Cites] Lab Invest. 2000 Apr;80(4):443-54 [10780661.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4463-8 [10781045.001]
  • [Cites] J Cell Biochem. 2000 Apr;78(1):112-20 [10797570.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16213-8 [10748043.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):118-23 [10886518.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):506-13 [10945499.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2132-44 [18381418.001]
  • [Cites] Dev Biol. 2008 Apr 15;316(2):302-11 [18325490.001]
  • [Cites] BJU Int. 2008 May;101(9):1071-5 [18070191.001]
  • [Cites] Can J Urol. 2008 Apr;15(2):3967-74 [18405443.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2552-60 [17968313.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Exp Mol Med. 2008 Apr 30;40(2):176-85 [18446056.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):195-201 [18386814.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2570-8 [18451218.001]
  • [Cites] Methods Mol Med. 2008;141:131-51 [18453088.001]
  • [Cites] Cell Cycle. 2008 Mar 15;7(6):706-13 [18461720.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jul;47(7):565-72 [18383208.001]
  • [Cites] Exp Cell Res. 2008 Jun 10;314(9):1973-9 [18448098.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):3-10 [18325755.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):450-8 [